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vidual process. Therefore, an indi-
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person’s health status including 
assessment of his/her medication is 
essential. This thesis investigated the 
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sessment, and especially the impact 
of a medication assessment in indi-
viduals aged ≥75 years focusing espe-
cially on the disparity on recognizion 
of adverse drug reactions by patients 
and their physician, the anticholiner-
gic adverse reactions, and the effect 
of CGA on drug use and orthostatic 
hypotension.
PASI LAMPELA
Improving Pharmacotherapy in Older
People – a Clinical Approach
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland
for public examination in ML1 Auditorium, Medistudia building, Kuopio,
on Friday, June 14th  2013, at 12 noon
Publications of the University of Eastern Finland
 Dissertations in Health Sciences
171
Clinical Pharmacology and Geriatric Pharmacotherapy Unit, School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
Kuopio
2013
Kopijyvä Oy
Kuopio, 2013
Series Editors:
Professor Veli-Matti Kosma, M.D., Ph.D.
Institute of Clinical Medicine, Pathology
Faculty of Health Sciences
Professor Hannele Turunen, Ph.D.
Department of Nursing Science
Faculty of Health Sciences
Professor Olli Gröhn, Ph.D.
                                    A.I. Virtanen Institute for Molecular Sciences
Faculty of Health Sciences
Professor Kai Kaarniranta, M.D., Ph.D.
Institute of Clinical Medicine, Ophthalmology
Faculty of Health Sciences
Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy)
School of Pharmacy
Faculty of Health Sciences
Distributor:
University of Eastern Finland
Kuopio Campus Library
P.O.Box 1627
FI-70211 Kuopio, Finland
http://www.uef.fi/kirjasto
ISBN (print): 978-952-61-1123-0
ISBN (pdf): 978-952-61-1124-7
ISSN (print): 1798-5706
ISSN (pdf): 1798-5714
ISSN-L: 1798-5706
III
Author’s address: Kuopio Research Centre of Geriatric Care
Clinical Pharmacology and Geriatric Pharmacotherapy Unit
School of Pharmacy, Faculty of Health Sciences
University of Eastern Finland
KUOPIO
FINLAND
Supervisors: Professor Risto Huupponen, M.D., Ph.D.
Department of Pharmacology, Drug Development and Therapeutics
University of Turku
TURKU
FINLAND
Professor Sirpa Hartikainen, M.D., Ph.D.
Kuopio Research Centre of Geriatric Care
Clinical Pharmacology and Geriatric Pharmacotherapy Unit
School of Pharmacy, Faculty of Health Sciences
University of Eastern Finland
KUOPIO
FINLAND
Reviewers: Professor Johan Fastbom, M.D., Ph.D.
Department of Neurobiology, Care Sciences and Society
Karolinska Institutet
STOCKHOLM
SWEDEN
Professor Kaisu Pitkälä, M.D., Ph.D.
Department of General Practice and Primary Health Care
Institute of Clinical Medicine
University of Helsinki
HELSINKI
FINLAND
Opponent: Professor Jaakko Valvanne, M.D., Ph.D.
School of Medicine
University of Tampere
TAMPERE
FINLAND
IV
VLampela, Pasi
Improving Pharmacotherapy in Older People – a Clinical Approach
University of Eastern Finland, Faculty of Health Sciences
Publications of the University of Eastern Finland. Dissertations in Health Sciences 171. 2013. 77 p.
ISBN (print): 978-952-61-1123-0
ISBN (pdf): 978-952-61-1124-7
ISSN (print): 1798-5706
ISSN (pdf): 1798-5714
ISSN-L: 1798-5706
ABSTRACT
The share of older persons is increasing, as people live longer. However, although age
correlates with comorbidity and disability, there is a marked heterogeneity among older
age groups in the level of clinical, functional, and social impairment, with individuals on a
spectrum  from  fit  to  frail.  In  addition,  the  response  to  medication  can  vary  among  older
persons due to age-associated changes the body and comorbid diseases. However, there is
rather limited information about effects of different medicines in this age group, as
medicines are generally evaluated in younger age groups. Therefore, an individualized
assessment of an older person’s health status including assessment of his/her medication is
essential.
   This thesis aimed to analyze the effect of comprehensive geriatric assessment (CGA), and
especially the impact of a medication assessment in individuals aged 75 years focusing
especially on (I) the disparity on recognizion of adverse drug reactions (ADRs) by patients
and their  physician,  (II)  the  anticholinergic  adverse  effects,  and the  effect  of  CGA on (III)
drug use and (IV) orthostatic hypotension.
   The data used in this study is derived from the Geriatric Multidisciplinary Strategy for the
Good Care of the Elderly (GeMS) study. GeMS was a prospective population-based,
randomized comparative study that took place in 2004-2007 in Kuopio, Finland. The
participants of the study (n=1000) were randomized to intervention (n=500) and control
(n=500) groups. All participants were interviewed annually by trained nurses and subjected
to  blood  pressure  measurements  and  blood  tests.  In  addition,  those  in  the  intervention
group  underwent  an  annual  CGA  including  physician’s  examination  with  medication
assessment, physiotherapist’s counselling and a nutritionist’s appointment if needed.
   At baseline, there was a great disparity between the patients and their physician in the
recognition of ADRs. The physicians identified ADRs in 24 % of the patients, while only 11
% of the patients reported ADRs. When potential anticholinergic ADRs were studied, there
was no association between the  serum anticholinergic  activity  (SAA) and potential  ADRs
(vision, saliva secretion, cognition, mood, physical function). Furthermore, when the SAA
was compared with scores from three ranked anticholinergic lists (Carnahan’s, Chew’s and
Rudolph’s),  only  the  list  of  Chew’s  was  associated  with  SAA.  However,  there  was  an
association  with  potential  ADRs  and  the  ranked  anticholinergic  lists.  The  CGA  did  not
decrease the number of drugs in use over a one-year period, although the numbers of
inappropriate drugs decreased, and in addition drug therapy became more rational. The
prevalence of orthostatic hypotension decreased as result of repeated interventions.
   In conclusion, a CGA with medication assessment has the potential to improve the health
of older persons. It should be tailored individually for each person.
National Library of Medine Classification: WT 30, WT 166, QV 56, WG 340
Medical Subject Headings: Geriatric Assessment; Drug Therapy; Pharmaceutical Preparations/adverse effects;
Hypotension, Orthostatic; Cholinergic Antagonists; Aged
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TIIVISTELMÄ
Eliniän pidentyessä ikääntyneiden osuus väestöstä kasvaa. Vaikka ikääntyminen onkin
yhteydessä lisääntyneeseen sairastavuuteen ja toimintakyvyn rajoituksiin, iäkkäiden
terveydentila vaihtelee terveistä monisairaisiin. Lääkkeiden käyttö ikääntyneillä on yleistä,
ja lääkkeiden vaikutukset voivat vaihdella suuresti ikääntymiseen liittyvien fyysisten
muutosten ja monien sairauksien vuoksi. Lääketutkimukset tehdään kuitenkin useimmiten
nuoremmissa ikäryhmissä, joten tietoa lääkkeiden vaikutuksista ikääntyneillä on vain
rajoitetusti. Tämän vuoksi iäkkään voinnin yksilöllinen yleisarvio, johon kuuluu kriittinen
lääkityksen kokonaisarvio, on oleellinen.
   Tässä väitöstutkimuksessa tutkittiin ikääntyneiden terveyden ja toimintakyvyn laaja-
alaisen arvioinnin (CGA) ja erityisesti siihen kuuluvan lääkityksen kokonaisarvion
vaikutuksia yli 75-vuotiaiden terveydentilaan. Tutkimuksessa keskityttiin erityisesti (I)
eroavaisuuksiin lääkkeiden haittavaikutusten (ADR) tunnistamisessa potilaan ja lääkärin
välillä, (II) lääkkeiden antikolinergisiin haittavaikutuksiin sekä CGA:n vaikutukseen (III)
lääkkeiden käytössä sekä (IV) ortostaattisen hypotension esiintyvyyteen.
Väitöskirjassa analysoitiin HHS (Hyvän Hoidon Strategia) -tutkimuksen tuloksia. HHS-
tutkimus toteutettiin Kuopiossa vuosina 2004-2007. Siihen kuuluneet 1000 yli 75-vuotiasta
henkilöä satunaistettiin interventio- ja kontrolliryhmiin (molempien ryhmien n=500).
Kaikki tutkimukseen osallistuneet kävivät vuosittain hoitajien vastaanotolla, jossa heidät
haastateltiin strukturoidun kysymyslomakkeen avulla. Heiltä mitattiin lisäksi verenpaine ja
otettiin verikokeita. Interventioryhmän jäsenet osallistuivat lisäksi CGA:an, johon
kuuluivat lääkärin tutkimus sekä lääkehoidon arviointi, fysioterapeutin ohjaus sekä
ravitsemusterapeutin antama ohjaus tarvittaessa.
Lähtötilanteessa potilaiden ja lääkärin näkemykset potilailla ilmenevistä ADR:sta
poikkesivat suuresti toisistaan. Lääkärit havaitsivat ADR:a 24 %:lla potilaista, kun taas
ainoastaan 11 % potilaista kertoi haitoista. Mahdollisilla antikolinergisillä haittavaikutuk-
silla (näöntarkkuus, syljeneritys, kognitio, mieliala, fyysinen toimintakyky) ei ollut yhteyttä
potilaiden seerumista mitattuun antikolinergiseen aktiivisuuteen (SAA). Verrattaessa SAA-
tuloksia kolmeen lääkeaineita antikolinergisyyden mukaan luokittelevaan listaan
(Carnahanin, Chew'n ja Rudolphin) ainoastaan Chew'n lista korreloi SAA-tulosten kanssa.
Nämä listat korreloivat kuitenkin mahdollisten antikolinergisten haittavaikutusten kanssa.
CGA ei vähentänyt käytössä olevien lääkkeiden määrää vuoden seuranta-aikana, mutta
lääkehoito muuttui rationaalisemmaksi sopimattomien lääkkeiden määrän vähentyessä.
Vuosittaiset CGA:t laskivat ortostaattisen hypotension prevalenssia.
   Yhteenvetona voidaan todeta, että CGA, johon kuuluu lääkityksen arviointi, voi parantaa
iäkkäiden terveydentilaa. CGA pitäisi aina toteuttaa yksilöllisesti.
Luokitus: WT 30, WT 166, QV 56, WG 340
Yleinen suomalainen asiasanasto: terveys; terveydentila; toimintakyky; lääkkeet; lääkehoito; haitat;
sivuvaikutukset; ortostaattinen hypotensio; antikolinergit; ikääntyneet
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1 Introduction
The share of aged people increases in the world. In 2010 approximately 7.6 % of the
world population was aged >65 years (in the developed countries their share of the
total population was 14.9 %, but in the developing countries only 5.8 %), and their
share is estimated to increase to 16 % in 2050 (Stegemann et al. 2010). In Finland,
their share is even higher, as 17.5 % of the total population of Finland was over 65
years at the end of 2010 (Eurostat 2012), and the number of persons aged 80 years or
more was 255 912. It is predicted that in the year 2060 the share of people living in
Finland aged >65 years will have increased up to 29 % (1.79 million), and there will
be a population of 463 000 persons aged >85 years (Official Statistics of Finland 2009).
   The age segment defined as older persons generally refers to people aged 65 years
and over. Aging is however a heterogenous and individual process (Cho et al. 2011).
There is a extensive heterogeneity among the age groups in the level of clinical,
functional and social impairment. However, it has been noted that comorbidity and
disability correlate with age (the likelihood of being frail increases with age), and it is
therefore sometimes helpful to consider three different patient groups: the young-
old (65-74 years), the old-old (75-84 years) and the oldest-old (>85 years) (Bernabei et
al. 2000).
   There are a number of medical conditions that are more prevalent among the older
persons, e.g. cardiovascular diseases (hypertension, heart failure, coronary heart
disease, myocardial infarction, stroke, peripheral arterial disease, atrial fibrillation),
dementia, Parkinson’s disease, depression, arthritis, diabetes, gastroesophageal
reflux disease, anemia, and thyroid disease (Yazdanyar and Newman 2009,
Khangura and Goodlin 2011, Logan 2011, Riley and Manning 2011, Moore et al.
2012). In addition, comorbidities are common, and these factors are often followed
by chronic drug therapy and polypharmacy imposing the challenges to their rational
treatment.
   Older persons are vulnerable to adverse drug reactions, which are considered a
potential cause of falls and the resulting hip fractures, as well as confusion and
cognitive impairments, urticaria, dementia, excitation, dehydration and hypotension
(Stegemann et al. 2010). However, older people, especially those who are frail, are
underrepresented in clinical drug trials (McLachlan et al. 2009), and therefore there
is a paucity of reliable information about the pros and cons of many drugs in older
persons. In addition, older persons are more susceptible to adverse effects and drug
interactions and these are more likely to occur in patients who would not be suitable
for inclusion in regulatory trials (Brodie 2001). The heterogeneity in outcomes in
older persons with differing comorbidity profiles emphasizes the need to provide
them with individualized information about the benefits and harms of different
diagnostic and treatment strategies (Fraenkel and Fried 2010).
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2.1 CHANGES IN AGING BODY
Aging is associated with a high degree of both intrapatient and interpatient
variability in drug response as a result of age-associated changes in organ function
and body composition, impairing homeostatic reserve and the risk of comorbid
diseases. However, chronological age as such is a poor predictor of variability in
responses to medicines (McLachlan et al. 2009). These variations are a result of age-
related changes in homeostasis, pharmacokinetics and pharmacodynamics.
2.1.1 Homeostasis
Homeostasis  is  the  ability  of  a  living  organism  to  control  its  internal  environment
despite fluctuations in the external environment (O’Neill 1997), and this includes e.g.
temperature homeostasis, water and electrolyte homeostasis (e.g. potassium,
sodium), and circadian function as well as sleep homeostasis (O’Neill 1997, Cajochen
et al. 2006, Gibson et al. 2009). One of the fundamental characteristics of aging is the
progressive reduction in homeostatic mechanisms (Turnheim 2004). With aging,
body responses to the external environment fluctuations may become exaggerated,
delayed in initiation or abnormal in phase (O’Neill 1997). Therefore, following some
kind of pharmacological perturbation of a physiological function, more time is
required to regain the original steady-state as counter-regulatory measures are
reduced (Turnheim 2004). This can be seen in e.g. orthostatic hypotension and
increased sensitivity to hypoglycemia in older patients with sulphonylureas.
2.1.2 Pharmacokinetics
Passive absorption in the intestine shows the least change with aging (Boparai and
Korc-Grodzicki 2011), but compounds permeating through the intestinal epithelium
by carrier-mediated transport-mechanisms (iron, calcium, vitamins, possibly
nucleoside drugs) may be absorbed at a lower rate in older persons (Turnheim 2004).
The rate of transdermal, subcutaneous and intramuscular drug absorption may also
decrease due to reduced blood perfusion.
   The most significant pharmacokinetic change in older persons is the reduction in
renal drug elimination, as glomerular filtration rate, tubular secretion, and renal
blood flow are all reduced (Turnheim 2004). In fact, renal function begins to decline
when people reach their mid-30s and continues to decline an average of 6-12
ml/min/1.73m2 per decade. This results in a decreased clearance of many drugs (e.g.
digoxin, water-soluble antibiotics and -adrenoceptor blockers, lithium, diuretics
and non-steroidal anti-inflammatory drugs) and the active metabolites of some other
medications (e.g. morphine) (Mangoni and Jackson 2004, Boparai and Korc-
3Grodzicki 2011). However, according to Stegemann et al. (2010), one third of
population displays a stable renal clearance, measured as GFR, between 30 and 80
years suggesting that diseases common in people over 65 years such as
hypertension, vascular diseases and diabetes may be more important than aging
itself (Stegemann et al. 2010). Renbase, a Finnish database about the use of drugs in
situations of renal failure, lists 487 drugs that should be avoided or for which dosage
should be modified in patients with renal failure. Renal function (as assessed by the
glomerular filtration rate, GFR) determination has traditionally been based on serum
creatinine levels using Cockroft-Gault or Modification of Diet in Renal Disease
(MDRD) equations which also incorporate age, sex and height and/or weight data.
However  both  equations,  but  especially  MDRD,  may  overestimate  GFR  in  older
persons (Spruill et al. 2008, Spruill et al. 2009, Van Pottelbergh et al. 2011). As the
muscular mass decreases in older persons, the use of creatinine is not optimal among
this age group. Therefore, also cystatin C has been used for estimating GFR.
Although cystatin C is not independent of body composition, it is not affected by the
muscle volume and seems to be a useful marker in the GFR estimation in older
persons (Fehrman-Ekholm et al. 2009, Modig et al. 2011). The optimal method for
GFR estimation especially in older patients is a topic of ongoing debate (Van
Pottelbergh et al. 2011).
   The distribution of drugs is altered due to changes in body composition. Lean
body mass and total body water become reduced with age, resulting as a lower
volume of distribution of hydrophilic drugs (e.g. digoxin and ethanol). Therefore,
lower doses may result in a higher drug concentration. On the other hand, the body
fat/water ratio increases during age and therefore lipid-soluble drugs (e.g.
benzodiazepines, amiodarone, verapamil) have a higher volume of distribution and
they will take a longer time to reach a steady-state and take longer to be eliminated,
potentially prolonging their duration of action. The relative change in the volume of
distribution for lipophilic drugs is more marked in men (body fat increase from 18 to
36 %) than in women (body fat increase from 33 to 45 %) (Turnheim 2004). Serum
albumin  is  an  important  carrier  for  many  different,  especially  acidic  drugs,  but  its
levels may significantly decrease with malnutrition or chronic diseases. Among
those drugs that are highly protein-bound (e.g. diazepam, phenytoin, warfarin,
salicylates) this results as an increase in the pharmacologically active unbound drug
concentration. On the other hand, basic drugs (e.g. propranolol and lidocain) are
bound to -1-glycoprotein and its concentration may increase during acute illnesses.
However,  the  clinical  relevance  is  probably  limited  since  the  transient  effect  of
protein binding on free plasma concentration is rapidly counterbalanced by its
effects on clearance (Mangoni and Jackson 2004).
   Metabolism occurs mostly in liver, and aging is associated with a reduction in the
first-pass metabolism due to decreased liver blood flow, size and mass (Boparai and
Korc-Grodzicki 2011). Therefore the bioavailability of those drugs that are
metabolized via phase I reactions (oxidation, reduction) by cytochrome P450 (CYP)
enzymes may be significantly increased. On the other hand, prodrugs (e.g. some
4angiotensin converting enzyme (ACE) -inhibitors, such as enalapril and perindopril)
need to be activated by liver enzymes, which may be slowed or reduced (Mangoni
and Jackson 2004). However, the interindividual variation in metabolic drug
clearance by CYP enzymes or phase I reactions exceeds the decline caused by aging
(Turnheim 2004). Unlike phase I reactions, the activities of the phase II reactions
(conjugation, acetylation) do not change with aging.
   These pharmacokinetic changes may be predictable, but the differences between
the age group (from fit to frail, with multiorgan dysfunctions) results in relatively
large variability in drug pharmacokinetics among older persons (Cho et al. 2011).
2.1.3 Pharmacodynamics
   Pharmacodynamics describes how drugs exert their effect at the site of action and
the time course and intensity of pharmacological effect (Boparai and Korc-Grodzicki
2011). It is determined not only by the concentration of the drug at the receptor, but
also by the drug-receptor interactions (which can involve variations in receptor
number and receptor affinity, second messenger responses and the ultimate cellular
response), variations in physiological or homeostatic mechanisms, and changes in
functional reserves. Age-related changes are more complex than pharmacokinetic
changes, and they tend to be drug class specific (Cho et al. 2011).
   The responsiveness of -adrenoceptors is preserved with advancing age (Mangoni
and Jackson 2004), but reduction in response of -adrenoceptor agonists results
apparently due to downregulation of -adrenoceptors in response to the elevated
serum noradrenaline levels (Turnheim 2004). However, Mangoni and Jackson
hypothesized that the reduced responses to -agonists and antagonists were
secondary to impaired -receptor function due to reduced synthesis of cyclic AMP
following receptor stimulation. The total number of receptors seems to be
maintained but the postreceptor events are changed because of alterations of the
intracellular environment (Mangoni and Jackson 2004). In addition, responsiveness
of adenosine A1-receptors and heart muscarinic receptor activity are reduced
(Turnheim 2004). However, for the most part, the mechanisms of pharmacodynamic
changes have not been well defined, e.g. the risk for major bleeding of those on
warfarin is significantly increased although there is little difference in its
pharmacokinetics in older patients (Cho et al. 2011).
   The baroreflex sensitivity to changes in blood pressure decreases with age (Gupta
and Lipsitz 2007). This makes older persons more vulnerable to orthostatic
hypotension and blood pressure fall caused by e.g. dihydropyridines and organic
nitrates (Kelly and O'Malley 1992, Corsonello et al. 2010).
   Brain weight becomes reduced by 20 % between the age of 20 and 80 years, and
neuronal  loss  occurs  in  several  brain  regions  (Turnheim  2004).  The  numbers  of
dopamine D2 and cholinergic receptors become decreased in the central nervous
system (CNS). The reduction of dopamine content and receptor abundance
predisposes to extrapyramidal symptoms in response of dopaminergic blockade by
neuroleptics. On the other hand, the reduction in acetylcholine content renders older
5persons more susceptible to cognitive impairment and other anticholinergic effects
e.g. of antipsychotics and tricyclic antidepressants. Advancing age is also associated
with increased sensitivity to the CNS effects of benzodiazepines, probably due to
GABAA-benzodiazepine receptor complex changes (Mangoni and Jackson 2003,
Turnheim 2004, Cho et al. 2011).
   These changes have been summarized in Table 1.
Table 1. Changes  in  aging  body  resulting  as  increased  susceptibility  to  adverse  drug
reactions.
Pharmacokinetic changes Examples
Absorption speed by active mechanisms may be decreased Iron, calcium, vitamins
Decrease of transdermal, subcutaneous and intramuscular
drug absorption rate
Reduction in renal drug elimination Digoxin, lithium
Increase of body fat/water ratio Benzodiazepines, verapamil
Changes in serum protein levels (albumin, -1-glycoprotein) Warfarin, propranolol
Reduction of first-pass metabolism in liver Enalapril
Pharmacodynamic changes  Examples
Reduction in -, A1- and heart muscarinic receptor activity
Decreased baroreflex sensitivity Organic nitrates, dihydropyridines
Reduction in the number of D2- and cholinergic
receptors in the CNS Haloperidol, metoclopramide
Neuronal loss in several brain regions
Decreased acetylcholine content Amitriptyline
Changes in GABAA-benzodiazepine complex Benzodiazepines
2.2 COMPREHENSIVE GERIATRIC ASSESSMENT
2.2.1 Definition and description
Comprehensive geriatric assessment (CGA) is characterized as a technique for
multidimensional diagnosis of vulnerable older persons with the purpose of
planning and/or delivering medical, psychosocial, and rehabilitative care
(Rubenstein et al. 1991). Its major purposes are to improve diagnostic accuracy,
optimize medical treatment, improve medical outcomes (including functional status
and quality of life), optimize living location, minimize unnecessary service use, and
arrange long-term case management. CGA is usually grouped into the four domains
of physical health, functional status, psychological health and socioenvironmental
parameters (Rubenstein 2004), and it is one of the cornerstones of modern geriatric
care (Ellis et al. 2011). CGA has been shown to be effective in comprehensive meta-
analyses (Beswick et al. 2008, Ellis et al. 2011). The main aspects of CGA are shown
in Table 2.
6Table 2. Main aspects of comprehensive geriatric assessment (CGA) (Wieland and Hirth
2003, Ellis and Langhorne 2005).
CLINICAL GOALS OF CGA MAJOR COMPONENTS OF CGA
 -To improve process of care Medical assessment
 -To improve outcomes of care  -Problem list
 -To contain costs of care  -Comorbid conditions and disease severity
 -Medication review
 -Nutritional status
DIFFERENT SPECIALISTS THAT MAY Assessment of functioning
TAKE PART IN A CGA TEAM  -Basic activities of daily living
 -Physician  -Instrumental activities of daily living
 -Nurse  -Activity/excercise status
 -Physiotherapist  -Gait/balance
 -Psychologist Psychological assessment
 -Social worker  -Mental status (cognitive) testing
 -Nutritionist  -Mood/depression testing
 -Occupational therapist Social assessment
 -Dentist  -Informal support needs and assets
 -Audiologist  -Care resource eligibility/financial assessment
 -Pastoral carer Environmental assessment
 -Home safety
 -Transportation and telehealth
   It has been postulated in early days of CGA, that geriatric evaluation should be
linked with strong long-term management if it were to be effective (Stuck et al.
1993). Subsequent studies and meta-analyses have later shown the beneficial effect of
in-hospital CGA wards to changes of being alive and in their own home up to a year
after hospital admission. These individuals were also less likely to become
institutionalized and to suffer death or deterioration, but more likely to experience
improved cognition (Baztán et al. 2009, Van Craen et al. 2010, Ellis et al. 2011).
However, inpatient CGA does not seem to reduce long-term mortality (Ellis and
Langhorne 2005). Outpatient CGA doesn’t seem to confer any survival benefit (Kuo
et al. 2004), but it can help older persons to live safely and independently (Beswick et
al. 2008). However, CGA has shown a favourable outcome in frail and pre-frail
community-dwelling older persons based on the frailty status and activities of daily
living by Barthel, although the results were not statistically significant (Li et al. 2010).
   An important issue in successful CGA is the adherence of both physician and
patient. However, compliance with CGA recommendations may be poor, with
adherence rates among both physicians and patients of only around 50 % (Gold and
Bergman 2000, Banning 2008). The adherence of physician may be enhanced with
effective geriatrician-physician communication, prioritizing and limiting the number
of recommendations and incorporating physician education and patient
empowerment strategies. On the other hand, patient adherence may be increased if
the physician has an understanding of the patient beliefs and resources, he/she uses
a  combination  of  methods,  simplifying  the  plan  and  taking  early  steps  to  facilitate
implementation. There should also be a continuum of formal and informal support
7for the patient to help him/her carry out the plan (Aminzadeh 2000). However, based
on their own clinical experience, Greveson and Robinson (2001) commented that
many patients referred to a community CGA service have difficult family
relationships, resulting in a high level of stress for informal carers and high demands
on primary- and community-care professionals. They often have poor psychological
adaptation to their physical frailty and are less likely to adhere to recommendations.
2.2.2 Medication assessment
Use of medicines by older people is high and increasing and the share of those
without any medication is small, 2-3 % (Barat et al. 2000, Jyrkkä et al. 2006). In fact,
almost 90 % of older persons are taking prescribed drugs. In addition, the use of
over-the-counter drugs is also common (72 %, Barat et al. 2000). Older persons also
take several different medicines, with the mean number of drugs in use varying
between 4.2 and 7.6 (Barat et al. 2000, Bregnhoj et al. 2007). There is no clear
definition for polypharmacy, and several different alternatives have been used
(Veehof et al. 2000, Cannon et al. 2006, Fialová and Onder 2009), although five or
more different drugs has often been used as the cut-off value (Muir et al. 2001,
Jyrkkä et al. 2006, Viktil et al. 2006). However, setting a strict cut-off to identify
polypharmacy is of limited value in a clinical setting, because the number of drug-
related problems increase in an approximately linear manner with the increase of
drugs used (Viktil et al. 2006).
   Polypharmacy has been associated with advanced age and co-morbidity, evidence-
based clinical practice guideline recommendations, and hospitalization (Sergi et al.
2011). Risk factors for polypharmacy include older age, poorer health and number of
healthcare visits (Hanlon et al. 2001), cardiovascular diseases, diabetes or stomach
symptoms, those who often take drugs (especially sedatives/hypnotics) without clear
indication and those who develop hypertension or atrial fibrillation over time
(Veehof et al. 2000). Furthermore, older people living in institutional care use more
medicines than their community-dwelling counterparts (Jyrkkä et al. 2006).
Polypharmacy can be defined as appropriate when many medicines may be used to
achieve better clinical outcomes for patients. However, inappropriate polypharmacy
is associated with negative health outcomes, and it occurs when older persons are
prescribed more medicines than are clinically indicated (Patterson et al. 2012).
   Although older persons use a high number of medications, they are often excluded
from  clinical  drug  trials.  This  causes  a  problem  since  extrapolation  of  results  from
younger patients or relatively healthy older individuals to older patients with
multiple concurrent illnesses does not provide sufficient data to allow a reliable risk-
benefit estimation (McLachlan et al. 2009, Cho et al. 2011).
   Adequacy of medication is an important factor when minimizing adverse drug
effects among all patients, but especially among frail older persons. Appropriate
prescribing  has  to  be  based  on  an  understanding  of  the  pathophysiology  of  the
problem and the pharmacology of the drugs available to treat it (Aronson 2004).
Spinewine et al. (2007) defined that three of the most important sets of values in
8judging appropriateness of prescribing are 1) what the patient needs and prefers, 2)
scientific, technical rationalism (including clinical pharmacology) and 3) the general
good (mixture of issues, including societal and family-related consequences of
prescribing). Suboptimal prescribing has been defined as overuse or polypharmacy,
inappropriate use, and underuse, and is associated with significant morbidity and
mortality.  In  particular,  inappropriate  prescribing  is  common  in  older  in-  and
outpatients (Hanlon et al. 2001).
   Therefore, an important part of the CGA is the medication assessment, where the
drugs in use by the patient are critically reviewed and modified if necessary.
Prescribing may be regarded as inappropriate when there exists an alternative
therapy that is either more effective or associated with a lower risk (Kaur et al. 2009).
The  medication  assessment  is  performed  by  a  physician,  who  (assisted  by  other
health care personnel if needed) evaluates the patient’s current medication along
with its indications and appropriateness as part of the clinical examination and
treatment planning (Ministry of Social Affairs and Health 2011). Finnish authorities
have stated that the adequacy of medication treatment should be regularly (at least
once a year) evaluated especially for individuals who use several medicines
simultaneously,  older  persons  and  other  special  groups  (Ministry  of  Social  Affairs
and Health 2007, 2011).
   The general factors associated with the use of inappropriate medication include
older age, female gender, lower educational level, lower household income, poor
self-related health, depressive symptoms, lower mini mental state examination
(MMSE)  score,  higher  number  of  visits  to  the  general  practitioner  per  year  and
higher number of drugs for the last month (Lechevallier-Michel et al. 2005a), and
higher price of newer medicines (Pitkälä et al. 2002). In addition, older people often
have multiple medical conditions and the appropriate treatment to one condition
may be contraindicated in the treatment of the second condition. Cholinesterase
inhibitors, for example, are recommended in treatment of Alzheimer’s disease (Popp
and Arlt 2011), but anticholinergics are an important medicine group in treatment of
chronic obstructive pulmonary disease (COPD) (Flynn et al. 2009). If the same
patient has both conditions, the recommended treatment would counteract against
each other and the treatment has to take this reality into consideration. In addition,
older persons with diabetes are at higher risk of hypoglycemia, and their treatment
should be individually tailored and treatment goals (in terms of HbA1c levels) might
therefore be higher than would be the case in younger adults (Schütt et al. 2012).
2.3 INAPPROPRIATE MEDICATION FOR OLDER PERSONS
Several criteria for identifying potentially inappropriate medications have been
published. They can be divided to explicit (criterion-based, e.g. Beers criteria) and
implicit (judgment-based, e.g. Medication Appropriateness Index (MAI)) criteria
(Hamilton et al. 2009). The oldest of those, Beers criteria (Beers et al. 1991) has been
9one  of  the  most  commonly  used  criteria  (Marcum  and  Hanlon  2012).  It  was
originally  developed  to  be  used  among  older  persons  (aged  65  years  or  more)
residing in nursing homes and included 30 therapeutic classes/medications. The first
update in 1997 (Beers et al. 1997) widened the criteria to include all older persons
regardless of residence. The second update (Fick et al. 2003) further widened the
criteria, which now included 48 medications/classes of ‘drugs-to-avoid’ and 20 drug-
disease interactions. The last update published at the beginning of 2012 includes 53
medications or medication classes and now include a new category; medications to
be used with caution in older adults (The American Geriatrics Society 2012 Beers
Criteria Update Expert Panel 2012). Canadian researchers have also developed their
own criteria (McLeod et al. 1997, Rancourt et al. 2004).
   Beers criteria have been developed in the USA, and therefore their usefulness in
other countries is limited, due to differences in drug availability, clinical practice,
socioeconomic levels and health system regulations (Laroche et al. 2007a). Therefore,
some European countries have also developed their own criteria. The first European
list of inappropriate medicines for older persons was published in Sweden in 2003
and updated in 2010 (Socialstyrelsen 2003, Socialstyrelsen 2010). The Swedish
criteria determined older persons as aged 75 years or more. Other European lists
include the French Laroche’s criteria (for persons aged 75 years or more) (Laroche et
al. 2007a), Screening Tool of Older Person's potentially inappropriate Prescriptions
(STOPP) criteria from Ireland for persons aged at least 65 years (Gallagher et al.
2008) and the recently developed Norwegian General Practice criteria (which is
partly based on the Beers criteria adapted for Norway (Nyborg et al. 2012). The
Finnish database of medication for the elderly was completed in 2010, and it
classifies the 350 medicines or combination medicines most commonly used in the
treatment of older adult patients. This database classifies not only inappropriate
medicines,  but  also  describes  medicines  suitable  for  older  persons  using  four
classification steps: suitable, limited evidence from clinical trials and/or clinical use
and limited efficacy for patients 75 years and over, appropriate under certain
conditions, and inappropriate (Bell et al. 2013).
   MAI was originally developed by Hanlon et al. 1992. It is based on 10 questions
about: 1) indication 2) effectiveness 3) dosage 4) direction 5) practicality 6) drug-drug
interactions 7) drug-disease interactions 8) duplication 9) duration and 10) expense.
A 3-point scale is used to rank each criterion, which enhances the usefulness of the
instrument (Kassam et al. 2003). There is a report that MAI is better at predicting the
risk of adverse drug events (ADE) than the Beers criteria (Lund et al. 2010).
However, there has also been criticism of the weighting of the scale; since if the drug
is ineffective for the medical condition (the second question), then the prescription is
inappropriate and none of the other questions matters (Aronson 2004).
   The differences in the different criteria mainly reflect differences in medication
availability and prescription patterns in the different countries (Chang and Chan
2011). STOPP criteria have been claimed to identify a higher proportion of patients
suffering adverse events related to inappropriate medication than Beers’ criteria
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(2003 update) (Gallagher and O’Mahony 2008, Hamilton et al. 2011). In addition, in a
comparison of the different criteria, the STOPP, Rancourt and Laroche came closest
to fully meeting the optimal explicit criteria (Chang and Chan 2011).
2.3.1 Home-dwelling persons
There are several studies which have investigated the quality of drug treatment in
the home-dwelling aged population. Use of inappropriate medication depends on
the criteria used, and the prescribing culture as well as the population of the country.
Beers criteria has been the most commonly used system to determine inappropriate
medications. In general, the use of at least one inappropriate medicine is found to be
common especially in older persons.
   The share of older persons with inappropriate medication according to Beers
criteria has ranged from 12.5 % to 49 % (Pitkälä et al. 2002, De Wilde et al. 2007,
Lund et al. 2010, Leikola et al. 2011). On the other hand, using the MAI criteria, up to
84 – 99 % of patients had one or more inappropriate ratings on their medication even
after exclusion of the ratings concerning the expense of medication (Bregnhoj et al.
2007, Lund et al. 2010).
   Factors  associated  with  inappropriate  medication  include  >3  drugs  in  use  and
depressive symptoms (Stuck et al. 1994). On the other hand, Steinman et al. (2006)
claimed that patients using fewer than eight medicines were more likely to be
missing  a  potentially  beneficial  drug  than  to  be  taking  a  medication  considered
inappropriate.
2.3.2 Hospitalized patients
Among hospitalized patients, Beers criteria have been widely used but also the use
of the Irish STOPP/START (Screening Tool of Alert doctors to the Right Treatment)
criteria have been common. When using Beers criteria, inappropriate medication
was considered to being used by 25 – 66 % of patients (Page II et al. 2006, Laroche et
al. 2007b, Gallagher and O’Mahony 2008), whereas with STOPP/START criteria their
share has been 35 – 77 % (Gallagher and O’Mahony 2008, Lang et al. 2010).
   Although up to 66 % of the patients in hospital may receive inappropriate
medication based on the Beers criteria, there does not seem to be any significant
connection between inappropriate medication and adverse drug reactions (ADR),
mortality, length of stay or discharge to higher levels of care (Onder et al. 2005,
Laroche et al. 2007b, Page II et al. 2006). For example, in the study of Page II et al.
(2006) 27.5 % of older patients in the internal medicine services were prescribed
medications listed by Beers. While 31.9 % of the patients experienced ADEs, only 9.2
% of the ADEs were attributed to the medications listed in the Beers criteria. Similar
results were found in a French study, in which the prevalence of ADRs was 16.4 and
20.4 % with patients without or with any inappropriate medicines based on modified
Beers criteria, respectively. Prior to admission, 66 % of patients were given at least
one inappropriate drug, but in only 5.9 % of all those receiving inappropriate
medications were the ADRs directly attributable to these drugs (Laroche et al.
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2007b).  It  seems  that  interventions  that  are  more  comprehensive  than  Beers  are
necessary to reduce the risk of ADEs and the associated morbidity and mortality in
the acute care of the elderly (Page II et al. 2006). When Beers and STOPP criteria
were used to identify hospital admissions caused by potentially inappropriate
medication, the STOPP criteria identified higher a proportion of patients than Beers
criteria (11.5 % and 6 %, respectively) (Gallagher and O’Mahony 2008). Budnitz et al.
(2011) estimated that 6.6 % of hospitalizations for ADEs could be attributed to
potentially inappropriate medications according to Beers criteria, and half of these
involved digoxin.
   There  are  few  reports  which  have  evaluated  the  impact  of  specialized  units  in
decreasing inappropriate medications. In the study of Saltvedt et al. (2005), patients
aged at least 75 years, admitted as emergencies to hospital were subjected to either a
general medical ward or to an interdisciplinary geriatric evaluation and
management (GEM) unit which consisted of geriatrician, residents, nurses, enrolled
nurses, occupational therapists, and a physiotherapist. Potentially inappropriate
medication (by Beers) at inclusion was noted in 10 %/9 % of patients in GEM
unit/medical ward, respectively. At discharge their share had decreased (4 %/6 %
GEM unit/medical ward), but the difference was not statistically significant. There
were more initiations of antidepressants, and more terminations of digitalis
glycosides, -receptor antagonists as well as antipsychotics in the GEM unit than in
general medical ward. On the other hand, a beneficial effect has been observed also
in the general medicine inpatient service at the Veterans Affairs medical center. Muir
et al. (2001) used visual intervention (medication grid) delivered to physicians
resulting a decrease in the number of medications in the intervention group by 0.92
per patient while it increased by 1.65 per patient in the control group.
   In a study conducted in internal medicine units in a Brazilian university hospital,
the medications most commonly involved in suspected ADRs were identified as
anti-infectious agents, drugs acting on the CNS, gastrointestinal tract and
metabolism (Camargo et al. 2006). On the other hand, in a study at the acute medical
geriatric unit of the university hospital in France, the most common inappropriate
medications in patients experiencing ADRs were anticholinergic antidepressants,
cerebral vasodilators, long-acting benzodiazepines and concomitant use of two or
more psychotropic drugs from the same therapeutic class (Laroche et al. 2007b).
   In a U.S. study examining hospitalizations due to recognized adverse drug events
in older persons, four medications or medication classes (warfarin, insulins, oral
antiplatelet agents, and oral hypoglycemic agents) were implicated in 67 % of
hospitalizations caused by ADEs (Budnitz et al. 2011).
2.3.3 Nursing-home residents
Older persons living in nursing homes are generally frail and at increased risk of
polypharmacy, side effects and drug-drug interactions; furthermore it has been
reported that drug use (drugs for the nervous system and sensory organs) tends to
increase after admission into a nursing home (Koopmans et al. 2003). The share of
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persons using inappropriate medication according to the Beers criteria has been in
the range of 13 – 43 % (Nygaard et al. 2003, Lapane et al. 2007). Cognitively intact
residents  have been found to  use  more scheduled drugs  than cognitively  impaired
individuals (Koopmans et al. 2003, Nygaard et al. 2003). When Nygaard et al. (2003)
reviewed drug use, 13 % were found to be using inappropriate medication according
to Beers criteria, but when the authors used their own criteria (which, in addition to
drugs listed by Beers, included 11 drugs that were not included in Beers criteria), the
prevalence of subjects on inappropriate drugs increased to 25.3 % (21.6 % vs. 44.2 %,
mentally impaired vs. intact). There was a weak association between the number of
drugs in use and the numbers of inappropriate drugs. However, an increase in drug
use does not necessarily translate into poor prescribing practices, but continuous
drug review is needed in this population (Koopmans et al. 2003).
   One  important  topic  is  the  use  of  antipsychotics,  which  is  common  in  nursing
homes, with a prevalence between 28 % to 80 % (Briesacher et al. 2005, Hosia-
Randell and Pitkälä 2005, Alanen et al. 2006a) as compared to a prevalence of less
than 10 % in home-dwelling persons aged 75 years or more (Desplenter et al. 2011).
It  has  been  claimed  that  there  may  not  be  adequate  indications  in  all  cases  and  a
critical evaluation of treatment may be lacking (Alanen et al. 2006a, 2006b); in the
study of Briesacher et al. (2005), only 42 % of those on antipsychotics were receiving
therapy in accordance with the nursing home prescribing guidelines.
   Frail persons living in nursing homes may often be admitted to hospitals for a
period of time. In a study by Boockvar et al. (2004), medication changes were
common during patient transfer between a hospital and a nursing home. The
changes were mostly discontinuations, followed by class changes and substitutions
(Boockvar et al. 2004), however hospitalization may also increase drug prescription
at discharge (Corsonello et al. 2007). Boockvar et al. (2004) reported that ADEs
attributable to medication changes occurred during 20 % of bidirectional transfers.
The  overall  risk  of  ADE/drug  alteration  was  4.4  %.  Most  ADEs  occurred  in  the
nursing home after readmission, and intervention at the time of nursing home
readmission holds the potential to prevent most ADEs.
   Schmader et al (2004) compared inpatient/outpatient GEM with usual care.
Outpatient GEM resulted in 35 % reduction in the risk of serious ADR after
discharge compared with usual care, but the inpatient geriatric unit had no effect.
Inpatient geriatric unit care reduced unnecessary and inappropriate drug use and
underuse,  while  outpatient  GEM care  reduced the  number  of  conditions  for  which
there were omitted drugs significantly during the outpatient period. When
compared with usual care, it seems that outpatient GEM reduces serious ADRs,
whereas inpatient and outpatient GEM reduces suboptimal prescribing in vulnerable
older patients.
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2.4 IDENTIFICATION OF ADVERSE DRUG REACTIONS BY
PHYSICIAN AND PATIENT
Adverse drug reaction (ADR) has been defined by the European Parliament as “a
response to a medicinal product which is noxious and unintended and which occurs
at doses normally used in man for the prophylaxis, diagnosis or therapy of disease
or for the restoration, correction or modification of physiological function” (Directive
2001/83/EC, Article 1). This definition is practically unchanged from the 40-year-old
definition issued by the World Health Organization (Edwards and Aronson 2000).
On the other hand, adverse drug event (ADE) is an adverse outcome that occurs
while a patient is taking a drug, but is not or not necessarily attributable to the drug
(Edwards and Aronson 2000). However, there is a wide variety in terms in use to
depicit patient safety related to medication, and unfortunately the different terms
(e.g. adverse drug reactions/events), are not used uniformly in the literature making
it difficult to compare the results of the studies (Pintor-Mármol et al. 2012).
   ADRs are common among hospitalized older patients, although more than 80 % of
ADRs leading to admission or occurring in hospital are type A (dose-related) in
nature, i.e. predictable from the known pharmacology of the drug and therefore
potentially avoidable (Routledge et al. 2003). In the meta-analysis of 39 prospective
studies among U.S. hospitalized patients in U.S., serious ADRs occurred in 6.7 % and
fatal ADRs in 0.3 % of all patients (Lazarou et al. 1998). An even higher prevalence of
ADRs was reported in the study of Camargo et al. (2006), where 43 % of patients in
internal medicine units had at least one suspected ADR. Among them, 20 % had
manifested before the patient was admitted and 80 % during hospitalization. Risk
factors  for  the  development  of  ADRs  include  follow-up  length  and  number  of
medications but not age, gender or number of diagnoses (Camargo et al. 2006). On
the other hand, Laroche et al. (2007b) concluded that a high number of drugs is the
main ADR facilitating factor, with the inappropriateness of drugs being a
subordinate factor.
   ADRs may have a major impact on the quality of life of older patients. ADRs may
arise from medication errors, but also the appropriate medication may provoke
ADRs (Ferner  and Aronson 2006).  It  has  been claimed that  only  a  small  amount  of
ADRs are ever detected (Hannan 1999). Furthermore, only a small amount of ADRs
are reported to the pharmacovigilance centre by general practitioners (Moride et al.
1997). The low detection rate of ADRs may be a result of the fact that only in some
cases  are  adverse  events  immediate  or  well  known,  while  other  events  may  be
delayed, unfamiliar or patients may not realize that the problem has anything to do
with the medication they are taking (Britten 2009, Lorimer et al. 2012). In addition,
sensitivity to physical symptoms varies between individuals (Britten 2009).
Furthermore, in the actual clinical setting physicians may not discuss about risks of
medicines with patients (Britten et al. 2004), although patients may want to be given
more information than they receive about adverse effects (Britten 2009). Although
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information about ADRs is available in leaflets, few people read them. Instead, they
prefer that their physician should inform them about ADRs (Lorimer et al. 2012).
   Furthermore, the method of data collection may dramatically influence the results
(Sheftell et al. 2004). Sheftell et al. demonstrated, that those subjects who did not self-
report adverse events after receiving triptan therapy are much more likely to report
positively if presented with a list of side effects. However, in randomized, placebo-
controlled trials of statin drugs, a significant number (4-26 %) of patients in the
control groups actually discontinued placebo use because of perceived adverse
effects. In fact, symptom rate in placebo groups have varied substantially across
trials and were often markedly lower than those found in the general population
(Rief et al. 2006).
   On the other hand, physicians may not detect ADRs at the same rate than patients
or nurses. Patients with rheumatoid arthritis (Gäwert et al. 2011) and depressed
outpatients (Zimmerman et al. 2010) report more ADRs/ADEs than are recognized
by their physicians. Furthermore, among patients undergoing chemotherapy, nurses
were more able to detect symptoms being self-reported by patients than identified
by the physicians (Cirillo et al. 2009). In fact, there is a report describing the
dichotomy in considering what is an ADR between physician and patient, agreement
being best in the easily observable and well-known ADRs e.g. alopecia and
stomatitis (Gäwert et al. 2011).
   ADR  studies  are  often  performed  in  younger  populations  or  in  patients  with  a
specific  illness,  and  thus  information  from  older  people  is  limited.  Oladimeji  et  al.
(2008) studied risk factors for self-reported ADEs using an internet survey from
persons aged >65 years; a significant percentage (18 %) reported an ADE (visit to
physician to report an unwanted reaction or medical problem in the past year). The
risk of self-reporting an ADE was related to being female, number of pharmacies
used by patients, symptoms experienced, concern beliefs about medicines and
having a graduate academic degree.
2.5 ANTICHOLINERGIC-LIKE ADVERSE DRUG REACTIONS
2.5.1 Physiology
Cholinergic neurotransmission occurs through the binding of the neurotransmitter
acetylcholine to either muscarinic or nicotinic receptors. However, the term
anticholinergic traditionally refers only to the effects of muscarinic receptor
antagonism (Gerretsen and Pollock 2011). G-protein-type muscarinic receptors are
widely distributed throughout the human body and mediate distinct physiological
functions according to location and receptor subtype (Abrams et al. 2006). In the
CNS, acetylcholine mediates many cognitive processes, e.g. attention, memory and
learning functions (Jakubik et al. 2008). Five different subtypes (M1-M5) of muscarinic
receptors are known (Alexander et al. 2011), and their distribution is shown in Table
3. All subtypes have been found in brain, and especially subtype M1, but also M2 and
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M4 have been linked to cognitive processes (Kay and Ebinger 2008). Cholinergic
transmission is particularly important in the processing of recent memories,
visuospatial and perceptual functions, and psychomotor speed but does not seem to
be involved in either language or executive functioning (Kay et al. 2005).
   In periphery, muscarinic receptors mediate many physiological functions, e.g.
dilatation of blood vessels and decrease in blood pressure, miosis, increase of
secretion of endocrine glands and bronchoconstriction.
Table 3. Muscarinic receptors in the CNS and other tissues (Kay et al. 2005).
General distribution in the CNS Non-CNS locations
M1 Abundant in cerebral cortex, hippocampus and
neostriatum; constitute 40-50 % of total acetylcholine
receptors
Salivary glands, symphatetic
ganglia
M2 Located throughout brain Smooth muscle, cardiac muscle
M3 Low levels throughout brain Smooth muscle, salivary glands,
eyes
M4 Abundant in neostriatum, cortex, and hippocampus Salivary glands
M5 Projection neurons of substantia nigra pars compacta
and ventral tegmental area, and hippocampus
Eyes (ciliary muscle)
2.5.2 Anticholinergic adverse effects
Due  to  the  wide  distribution  of  muscarinic  receptors,  anticholinergic  drugs  may
evoke a variety of ADRs (Table 4). Anticholinergic drugs can be either lipid-soluble
tertiary ammonium compounds (e.g. atropine and dicyclomine) or lipid-insoluble
quaternary ammonium compounds (e.g. tiotropium bromide). Lipid-soluble
anticholinergics have more systemic side-effects than lipid-insoluble anticholinergics
(Flynn et al. 2009). Anticholinergic ADRs can be divided into peripheral (e.g. blurred
vision, dry mouth, urinary retention, constipation, tachycardia and atrial fibrillation)
and central ADRs (Wawruch et al. 2012). Central anticholinergic ADRs occur, when
anticholinergic drug penetrates through the blood-brain barrier into the CNS. In
general, they may include drowsiness, confusion, delirium and cognitive decline.
Table 4. Adverse effects of anticholinergic medication (Lieberman 2004, Penttilä et al.
2005a).
Peripheral anticholinergic side-effects Central anticholinergic side-effects
Decreased salivation Impaired concentration
Decreased bronchial secretions Confusion
Decreased sweating Attention deficit
Increased pupil size Memory impairment
Inhibition of accommodation
Increased heart rate
Difficulty urinating (detrusor muscle relaxation,
trigone and sphincter contraction)
Decreased gastrointestinal motility
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2.5.3 Measurement of anticholinergicity
Determination of an anticholinergic drug effects and their concentrations in serum
has been challenging (Mangoni et al. 2012). In addition to ‘pure’ anticholinergics (e.g.
atropine, scopolamine, tropicamide, oxybutynin, darifenacin, tiotropium), many
drugs possess anticholinergic properties, thus increasing the risk of anticholinergic
ADRs. In addition, there may be several drugs whose anticholinergic properties are
not known. Therefore, there is a wide variety on different studies about drugs
classified as anticholinergics (e.g. Carnahan et al. 2006, Chew et al. 2008, Rudolph et
al. 2008).
   Several different in vivo methods (e.g. saliva or sweat secretion, papillary reflex or
heart rate variability) have been applied to measure anticholinergic effects.
However, none of these methods is specific for changes in cholinergic
neurotransmission, and it has been recommended that they should be used together
with subjective assessments of anticholinergic effects (Penttilä et al. 2005a, 2005b).
Two different approaches are discussed below.
2.5.3.1 The Serum Anticholinergic Activity (SAA) assay
Binding of different drugs to muscarinic receptors has long been studied in vitro e.g.
by using carbachol-induced contractions in guinea-pig ileum (Shein and Smith 1978)
and in isolated fundus of rat stomach (Atkinson and Ladinsky 1972). In addition,
radioactive ligands, such as [3H]-N-methyl-4-piperidyl benzilate (Rehavi et al. 1977),
3H-propyl benzilyl choline mustard (Fjalland et al. 1977) and 3H-atropine (Golds et
al. 1980) have been used to determine binding to muscarinic receptors obtained from
mouse or rat brain. However, especially 3H-quinuclidinyl benzylate (QNB) has been
widely used in rat brain homogenate (Yamamura and Snyder 1974, Snyder and
Yamamura 1977, Hyslop and Taylor 1980). Tune and Coyle (1980) developed the
serum anticholinergic activity (SAA) assay that is based on the use of QNB. This
compound  has  affinity  for  all  muscarinic  receptors,  and  therefore  binds  to
muscarinic receptors in rat brain homogenate. When serum containing potent
muscarinic antagonists is added to the QNB-homogenate, the specific binding of
QNB is reduced in proportion to the concentration of the displacing agents. A
decrease in the radioactivity can be used to determine the potency of antimuscarinic
agent by comparing results to a standard curve of displacement obtained with
known amounts of atropine. This has remained as the most widely utilized assay for
quantifying anticholinergic load (e.g. Tune and Coyle 1981, Mondimore et al. 1983,
Flacker et al. 1998, Pollock et al. 1998, Chengappa et al. 2000, Mulsant et al. 2003,
Carnahan et al. 2006, Chew et al. 2006).
   There is extensive variance in the published SAA results, and several studies have
expressed  the  units  of  SAA  in  different  ways  making  the  synthesizing  of  these
studies more difficult (Carnahan et al. 2002a). In addition, the measured SAA don’t
necessarily reflect the medication that has been used by patients. E.g., in the study of
Mulsant et al. (2003) 10 % of the home-dwelling population had no detectable SAA
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activity, although 38 % of these persons were taking anticholinergic drugs. On the
other hand, when SAA was tested from acutely ill older patients not taking any
recognized anticholinergic medication, 80 % of them had detectable SAA activity
(Flacker and Wei 2001). Previously published results are presented in Table 5.
   SAA levels have been associated with anticholinergic adverse effects, e.g. decrease
in MMSE score among community-dwelling aged persons (Mulsant et al. 2003) and
depressed patients after electroconvulsive therapy (Mondimore et al. 1983). In
addition,  an association with higher  SAA levels  and delirium has  been reported in
surgical patients (Tune et al. 1981, Golinger et al. 1987) and in acutely ill older
inpatients (Flacker et al. 1998). Higher SAA levels are also associated with greater
impairment in self-care capacity among nursing-home residents with dementia
(Rovner 1988). However, the levels of SAA vary substantially between the studies
(Table 5).
   An increase of SAA has been associated with dry mouth, tachycardia, constipation
and urinary disturbances, but not with MMSE or auditive working memory as
measured with digit span performance, although visuomotor performance has
declined (Pollock et al. 1998, Chengappa et al. 2000, Mulsant et al. 2004). In the recent
study by Mangoni et al. (2012), SAA was positively associated with the Katz
activities of daily index (ADL) score, but not with morbidity as measured by the
Charlson comorbidity index.
   Among older persons (mean age 86±7 years), there was a significant association
between the score of drugs classified with Anticholinergic Drug Scale and the SAA
results (Carnahan et al. 2006). The SAA method has also been used to determine
anticholinergic effects of drugs in vitro. Tune et al. (1992) analysed 25 drugs using a
standard concentration (10-8 mol/l). The highest activity was found with cimetidine
(3 pmol/ml of atropine equivalents). However, this single concentration may not be
clinically  relevant  for  many  of  the  drugs  studied.  Chew  et  al.  determined  six
clinically relevant concentrations for 107 medications and used these concentrations
to estimate the anticholinergic activity of these drugs (Chew et al. 2006, 2008).
   In general, the results about SAA levels and anticholinergic adverse effects are
mixed. This may result from several factors. Oral daily dosages generally do not
correlate with plasma concentrations, which are the result of individual
pharmacokinetic variations (Schor et al. 1992). Although SAA has been shown to
correlate with anticholinergic activity measured in the cerebrospinal fluid (Plaschke
et al. 2007), different drugs may have different abilities to penetrate into the CNS
and thus provoke CNS-related symptoms and the relevance of their measurement
from peripheral blood sample (which SAA uses) is questionable. SAA measures the
displacement  of  QNB  from  muscarinic  samples,  but  one  must  bear  in  mind,  that
QNB is displaced not only by cholinergic antagonists but also by agonists (Carnahan
et al. 2002a). In addition, the biological membranes used in the SAA assay are
obtained  from  rat  cortex  and  striatum.  In  these  areas,  two  thirds  of  muscarinic
receptors belong to M1 and  M4 subtypes (Levey 1993). Therefore, SAA may not
necessarily  predict  responses  to peripheral  effects,  such as M3-mediated salivation
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and eye contractibility. In addition, it is possible that patients receiving the highest
number of anticholinergic drugs may also be best able to tolerate those compounds
(Teramura-Grönblad et al. 2011). Furthermore, SAA activity has also been
demonstrated in patients who are not taking any recognized anticholinergic
medications (Flacker and Wei 2001). It is possible that at least some of the detected
SAA activity results from clinically important endogenous anticholinergic
substances, such as dynorphin A, myelin basic protein, protamine and cortisol
(which is known to increase during stress) that have been shown to have muscarinic
activity in vitro (Flacker and Wei 2001, Carnahan et al. 2002a). Therefore,
anticholinergic medications are apparently not the only determinant of SAA, and it
is important to make a careful consideration in the interpretation of findings using
the SAA assay (Carnahan et al. 2002a).
2.5.3.2 Lists of anticholinergic drugs
Tune  et  al.  (1992)  took  the  first  step  in  the  listing  of  anticholinergic  properties  of
different drugs measured with the SAA assay, as they estimated the anticholinergic
effects of 25 drugs. Since then, several ranked lists of anticholinergic drugs have
been developed; those published in the 2000s are presented in Table 6.
   Han et al (2001) studied medical inpatients with delirium using the Class of Drug
developed by Summers (1978) and a clinician-rated anticholinergic score, where they
established a list of 340 medications including those used in their population and
those reported to have an anticholinergic effect from the literature. Then, three
geriatric psychiatrists independently rated the anticholinergic effect of drugs on a
scale from 0 to 3. They used the same anticholinergic score with community-
dwelling men with hypertension (Han et al. 2008). Medications that were used in the
study  population  but  were  not  included  in  the  score,  were  reviewed  and  rated  by
three geriatricians. Anticholinergic exposure was associated to delirium symptom
severity and verbal memory as well as executive function.
   Based on the work of Han et al. (2001), Carnahan and his colleagues developed the
Anticholinergic Drug Scale (ADS); the scores of this scale have been found to
associate with the SAA results (Carnahan et al. 2002b, Carnahan et al. 2006). The
ADS classifies drugs between 0-3 based on their anticholinergic activity. The ADS
includes 536 drugs, of which 117 exhibited anticholinergic activity.
   Minzenberg et al. (2004) ranked 28 psychiatric drugs in use by schizophrenia
patients. For these drugs, they established a pharmacological index (calculated from
published studies reporting in vitro brain muscarinic receptor antagonism) and a
clinical index (based on a panel of 10 practicing psychiatrists with extensive
experience in clinical psychopharmacology). They rated the drugs’ anticholinergic
potencies relative to 1 mg benztropine mesylate. Both indexes highly correlated with
each other and also with decreased neuropsychological measures.
   In  the  study  by  Ancelin  et  al.  (2006),  the  anticholinergic  burden  of  the  home-
dwelling  study  population was  quantified by  a literature  review including known
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anticholinergic drugs with their serum anticholinergic activity where available. Then
each  participant’s  records  were  examined  by  a  pharmacologist,  physician  and
biologist resulting a classification of the anticholinergic burden between 0-3. The
study participants had 27 different anticholinergic drugs in use. These workers
reported that those subjects continuously using anticholinergic drugs displayed
significant deficits in cognitive functioning.
   The Anticholinergic Risk Scale (ARS), developed by Rudolph et al. (2008), includes
49 anticholinergic drugs. For the list, the 500 most prescribed medications within the
Veterans Affairs Boston Healthcare System were reviewed by a geriatrician and 2
geropharmacists to identify drugs with known potential for evoking anticholinergic
adverse effects (excluding topical, ophthalmic, otologic, and inhaled drugs). These
drugs were then subjected to a literature and database search, after which they were
rated 0-3 according to their anticholinergic potential. They reported a dose-response
relationship with higher ARS scores and anticholinergic ADEs, both central (falls,
dizziness and confusion) and peripheral (dry mouth, dry eyes, constipation) in
patients aged 65 years and more. Recently, Lowry et al. (2011a) reported that
institutionalization, the Charlson comorbidity index and non-antimuscarinic
polypharmacy were associated with the ARS in older hospitalized patients, but
increasing age and dementia were negatively associated with ARS score. Higher
ARS scores have been found to associate in poorer physiological well-being
(Teramura-Grönblad et al. 2011) and they have been negatively associated with
several components of the Barthel Index. They also predict in-hospital mortality in
the presence of hyponatremia (Lowry et al. 2011b), and 3-month mortality among
older hip fracture patients (Mangoni et al. 2012). However, higher ARS scores did
not  seem  to  be  associated  with  mortality  in  older  persons  living  in  long-term  care
(Kumpula et al. 2011).
   The Anticholinergic Cognitive Burden Scale (ACBS) devised by Boustani et al.
(2008) is a tool developed explicitly for categorizing drugs according to the severity
of  their  cognitive  effects.  ACBS  is  based  on  a  systematic  literature  review
supplemented by input from an expert panel of clinicians, and it focuses on central
rather than peripheral anticholinergic effects. In the study of Kolanowski et al.
(2009), no association was found between ACBS and engagement in activity of
nursing-home residents with dementia. In addition, use of anticholinergic
medications  determined  by  ACBS  did  not  increase  the  risk  of  incident  delirium  in
hospitalized older adults with cognitive impairment (Campbell et al. 2011), but it did
increase the cumulative risk of cognitive impairment (as measured by a decline in
the MMSE score) and mortality (Fox et al. 2011).
   The Drug Burden Index (DBI) has been developed to measure anticholinergic and
sedative medication burden among persons aged 70-79 years (Hilmer et al. 2007). It
subdivides  medicines  into  3  groups  with  respect  to  risk:  1)  drugs  with
anticholinergic and 2) sedative effects, and 3) total number of medications. Drugs
were identified from a literature search. They demonstrated that exposure to
anticholinergic   and   sedative   drugs   was   associated   with  poorer   physical  and
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cognitive function in community-dwelling older people. It was also associated with
falls, incontinence and geriatric depression scale (GDS) but not with MMSE (Wilson
et al. 2011), slower walking speed, poorer performance on chair stands and TUG as
well as lower scores in instrumental activities of daily living (IADL) and Barthel
index (Gnjidic et al. 2011). DBI has also been able to predict length of stay in hospital
but not in-hospital mortality (Lowry et al. 2012).
   Chew et al. (2008) measured in vitro the anticholinergic activity of 107 medications
commonly used by older persons. They used pharmacokinetic data to translate the
relationship between concentration and anticholinergic activity into an estimated
relationship between the dose and anticholinergic activity.
   However, despite the advantages of the antimuscarinic drug scoring systems
(limited training required, effortless use by healthcare professionals in various
healthcare  settings,  and  the  capacity  to  predict  outcomes  over  and  above  crude
measures of antimuscarinic drug exposure), several issues limit their widespread
application in clinical practice. These systems have been tested only in limited
healthcare settings, follow-up measurements are rare, and the calculation of
anticholinergic exposure is time-consuming since there is no software that
automatically calculates the score. In addition, some drugs (e.g. olanzapine) have
affinity also to other receptors than muscarinic receptors, so it is difficult to ascertain
whether  the  effects  of  these  drugs  are  primarily  due  to  their  affinity  to  the
muscarinic receptors (Mangoni 2011).
2.5.4 Use of anticholinergics
Anticholinergic drugs block muscarinic receptors. They are clinically used in the
treatment of overactive bladder (Abrams et al. 2006) and chronic airway diseases like
asthma and COPD (Barnes 2004, Flynn et al. 2009). Other indications include topical
use in ophthalmology, treatment of motion sickness and in hospitals to treat
bradycardia, and in treatment of organophosphate poisoning. There are also drugs
(e.g. amitriptyline and quetiapine) in which anticholinergic properties are unwanted
adverse effects.
   The use of anticholinergic drugs varies based on the setting. Among community-
dwelling older persons, 9 – 37 % use at least one anticholinergic medication
(Lechevallier-Michel et al. 2005b, Ancelin et al. 2006, Ness et al. 2006, Hilmer et al.
2007, Sittironnarit et al. 2011). Among those living in institutionalized care, the
numbers of subjects taking anticholinergics has been reported as being between 35 –
82 %, with the highest amounts being reported among those with dementia (Seifert
et al. 1983, Kolanowski et al. 2009, Kumpula et al. 2011).
   Hospitalization has been found to lead to a significant increase in the prevalence of
anticholinergic medicine users (10.5 % -> 14.2 %, admission -> discharge) among
older persons (Wawruch et al. 2012). It was stated that the most important risk
factors of using anticholinertic drugs were immobilization, urinary incontinence and
retention, constipation, gastroduodenal ulcer disease as well as neurologic and
psychiatric comorbidities (depression, Parkinson’s disease, epilepsy). Tramadol was
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the most frequently prescribed drug with anticholinergic activity. Most
anticholinergic  drugs  recorded  were  CNS  drugs,  H2-antihistamines and
antispasmodics.
   Patients with dementia are more likely to use anticholinergics than matched
controls (Roe et al. 2002). Dementia patients are often treated with cholinesterase
inhibitors  (ChEI)  such  as  donepezil,  galantamine  and  rivastigmine  (Popp  and  Arlt
2011). However, compared with individuals not having ChEIs, those on ChEIs have
an increased risk of subsequently receiving anticholinergic drugs (4.5 % vs. 3.1 % for
those with or without ChEIs, respectively) (Gill et al. 2005). Johnell and Fastbom
(2008) performed a register-based survey including 700 000 older persons and came
to similar conclusions (9 % of those in ChEIs were using anticholinergic drugs vs. 5
% not on ChEIs). Furthermore, a recent report by Teramura-Grönblad et al. (2011)
reported concomitant use of anticholinergic drugs and ChEIs in 10.7 % of older
persons living in residential care. The use of ChEIs is associated with an increased
risk of receiving an anticholinergic drug to manage urinary incontinence, and
urinary antispasmodics have been the most extensively used anticholinergic drug
among those receiving ChEIs (Gill et al. 2005, Johnell and Fastbom 2008), the other
common anticholinergics being non-selective monoamine reuptake inhibitors and
hydroxyzine (Johnell and Fastbom 2008). Although incontinence is a known adverse
effect of ChEIs, concurrent use of anticholinergic drugs and ChEIs should be kept to
an absolute minimum since anticholinergic drugs are likely to reduce the already
small effect of ChEIs on cognition (Johnell and Fastbom 2008).
2.5.5 Effects of anticholinergics on measured outcomes
Older people are thought to be particularly vulnerable to the central ADEs of
anticholinergic drugs. In general, conditions for which anticholinergic medications
tend  to  be  prescribed,  such  as  urinary  incontinence  or  chronic  obstructive
pulmonary disease, typically occur in later life (Gerretsen and Pollock 2011).
However,  there  may also  be  some age-specific  changes  in  the  CNS.  Aging reduces
the  number  of  muscarinic  receptors  in  the  brain,  and  regions  rich  in  muscarinic
receptor density, the corpus striatum and the cortical mantle show a greater rate of
decline (up to 50 %) than those areas that have a relatively low number of muscarinic
receptors (thalamic, hippocampal and cerebellar regions) (Dewey et al. 1990). In
addition, many conditions that are common among older persons (diabetes,
Alzheimer’s disease, Parkinson’s disease, cerebral stroke and head injuries) may
increase the permeability of blood-brain barrier and in that way the brain
penetration of anticholinergics may increase (Kay et al. 2008, Farrall and Wardlaw
2009, Stolp and Dziegielewska 2009, Weiss et al. 2009). Furthermore, individuals
with apolipoprotein E4 allele, which is a major risk factor for Alzheimer’s disease,
have lower cognitive function as a group, and therefore may be more vulnerable to
anticholinergic adverse effects (Uusvaara et al. 2009).
   Anticholinergic drugs have been associated with decreased functional abilities as
measured with ADL (Kumpula et al. 2011, Teramura-Grönblad et al. 2011, Lowry et
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al. 2011b, Lowry et al. 2012, Koshoedo et al. 2012) and IADL (Han et al. 2008). The
use of anticholinergic drugs is associated with poor psychological well-being
(Kumpula et al. 2011). However, among dementia patients, use of anticholinergics
has been associated with decreased self-care capacity (Rovner et al. 1988) but not
with engagement in activity, which is an important indicator of the quality of life in
patients with dementia (Kolanowski et al. 2009).
   There  are  mixed  results  with  anticholinergics  and  cognitive  functions.  Some
studies have reported a decrease in MMSE score (Mulsant et al. 2003, Uusvaara et al.
2009). In addition, the risk of cognitive decline after electroconvulsive therapy
(measured as an MMSE score decrease of at least 2 points) increased with elevated
serum anticholinergic activity levels (Mondimore et al. 1983). In the study of Lu and
Tune (2003) with Alzheimer disease patients, chronic exposure to anticholinergics
decreased MMSE score at 2 years. There are also studies where anticholinergic drugs
have had no effect on MMSE score (Miller et al. 1988, Sittironnarit et al. 2011). In
addition, Lechevallier-Michel et al. (2005b) reported an only barely statistically
significant  decrease  in  MMSE  on  persons  with  anticholinergics.  MMSE  is  a
measurement tool of global cognitive function, but it appears to be less useful in
detecting mild or transient impairment of the sort that often becomes clinically
important in the early phases of drug toxicity (Miller et al. 1988). Minzenberg et al.
(2004) used WAIS-R to determine global cognition, and anticholinergic medication
had no effect on this parameter. In addition, in some studies anticholinergic drugs
have had no effect on working memory. The results concerning anticholinergics and
visuomotor  functions  are  mixed,  ranging  from  no  effect  to  a  decrease.  In  addition,
tests about executive functions have produced mixed results. Verbal memory and
learning, as well as verbal fluency are often unaffected by anticholinergics although
some  decrease  has  also  been  found.  Visuospatial  functions  may  be  impaired  or  be
unaffected  by  anticholinergics.  Visual  memory  is  mainly  reduced  by  the
anticholinergics. Language functions are either unaffected or decreased (For these
results, see Table 7).
   The use of anticholinergics has been associated with delirium in presurgical and
postoperative patients (Tune et al. 1981, Miller et al. 1988) and patients with acute
stroke (Caeiro et al. 2004), although no association was found in older patients at
nursing home or in acute care ward (Schor et al. 1992, Luukkanen et al. 2011). In the
older patients already diagnosed with delirium, exposure to anticholinergic
medications has been independently and specifically associated with a subsequent
increase in the severity of delirium symptoms (Han et al. 2001). However, in the
study of Seifert et al. (1983), anticholinergics were not associated with confusion
among older nursing-home residents (Table 8). On the other hand, the use of
anticholinergics has been found as a strong predictor of mild cognitive impairment,
but  it  did  not  increase  the  risk  of  dementia  in  the  8-year  follow-up  (Ancelin  et  al.
2006).
   The use of anticholinergics has not been associated with increased mortality in
older  persons  in  long-term  residential  care  (Kumpula et al. 2011, Luukkanen et al.
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2011) or in older patients with stable cardiovascular disease (Uusvaara et al. 2011), but
among older male hip-fracture surgery patients, their use increased mortality (Panula et al.
2009).
   However, one must bear in mind that anticholinergic-type effects may be commonly
experienced also in individuals without anticholinergics in use. The study of Ness et al.
(2006) compared anticholinergic symptoms between those subjects on anticholinergics and
without anticholinergics, and the mean number of anticholinergic symptoms was 3.1 and
2.5 (those with and without anticholinergics, respectively). Only two symptoms, dry mouth
and constipation, were more prevalent in the anticholinergic group. The frequencies of
drowsiness, dry eyes and dry mouth were common in both groups.
2.6 ORTHOSTATIC HYPOTENSION
Orthostatic hypotension (OH) is a common manifestation of blood pressure dysregulation
(Robertson 2008). It has been defined as a decrease of systolic/diastolic BP > 20/10 mmHg
measured 1 or 3 minutes after standing up from a supine position (Consensus statement
1996). OH can be divided into acute OH (which is usually secondary to medication, fluid or
blood loss, or adrenal insufficiency) and chronic OH (frequently due to altered blood
pressure regulatory mechanisms and autonomic dysfunction) (Gupta and Lipsitz 2007).
However, there is also a faster form of OH which is called initial OH. This occurs
immediately upon standing and typically passes within a few seconds but it may be
associated with syncope in susceptible individuals. The slower form of OH, called delayed
OH develops between 5 min and 45 min after taking an upright posture (Robertson 2008).
Among  older  persons,  there  is  considerable  variation  in  OH  over  time,  being  most
prevalent in the morning when the individual first arises (Ooi et al. 1997). OH is associated
with significant morbidity and mortality (Masaki et al. 1998, Gupta and Lipsitz 2007,
Verwoert et al. 2008) and it is an independent risk marker for cardiovascular disease
(Benvenuto and Krakoff 2011) and atrial fibrillation (Fedorowski et al. 2010a). In addition, it
is associated with the risk of coronary heart disease (Verwoert et al. 2008) and stroke
(Eigenbrodt  et  al.  2000).  Furthermore,  in  older  nursing  home  residents,  OH  is  also  an
independent risk factor for recurrent falls (Ooi et al. 2000).
   Postprandial hypotension is often found in patients with orthostatic hypotension (Senard
et al. 2001). This is also common in geriatric patients and an important but under-
regocnized cause of syncope. Postprandial hypotension occurs within 2 hours after a meal
(Luciano et al. 2010).
2.6.1 Pathophysiology
In healthy people, approximately 500-1000 ml of blood is transferred below the diaphragm
upon assuming an erect posture, leading to decreased venous return to the heart, reduced
ventricular  filling,  and  a  transient  decrease  in  cardiac  output  and  blood  pressure.  This
triggers the activation of both high-pressure baroreceptors in the carotid sinus and aortic
arch, and low-pressure receptors in the heart and lungs, resulting in increased sympathetic
outflow and decreased parasympathetic outflow from the CNS, restoring cardiac output
and blood pressure by increasing heart rate and vascular resistance (Gupta and Lipsitz
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2007, Medow et al. 2008). In addition, there is an activation of the renin-angiotensin system,
and consequent aldosterone release (Robertson 2008). Heart rate, stroke volume and
vascular resistance influence to the blood pressure, and therefore impairments in the
response of any of these parameters during postural change may result in OH (Gupta and
Lipsitz 2007).
   Aging is associated with a decrease in baroreflex sensitivity, resulting as a diminished
heart rate response and an impaired 1-adrenergic vasoconstrictor response to sympathetic
activation. In addition, age-related reduction in parasympathetic tone results in less
cardioacceleration during the vagal withdrawal that normally occurs with standing.
Furthermore, the aged heart becomes stiff and non-compliant which results in an impaired
diastolic filling. Aging is associated with a reduction in renin, angiotensin, and aldosterone,
and an elevation in natriuretic peptides. This decreases the ability of the kidneys to
conserve salt and water during periods of fluid restriction or volume loss, leading to rapid
dehydration. They all greatly increase the risk of hypotension. Furthermore, systolic blood
pressure tends to increase with age, and this further impairs adaptive responses to
hypotensive stresses (Gupta and Lipsitz 2007).
   In addition to these physiological changes, there are also pathologic causes for OH. These
are secondary to central or peripheral nervous system diseases that result in autonomic
insufficiency (Gupta and Lipsitz 2007) (Figure 1).
2.6.2 Prevalence and risk factors of OH
Orthostatic hypotension (OH) has a major effect on the quality of life of older individuals in
whom it is a common condition with a prevalence ranging from 5 % to 30 % (Low 2008),
although some conditions may increase the prevalence even further. In the older
population, OH-related hospitalization rates are higher in men than in women, probably
due to the better cerebral autoregulation in females (Deegan et al. 2011). In the study of Ooi
et al. (1997), OH occurred in more than half of frail, elderly nursing home residents. Aging
increases prevalence of OH (Rutan et al. 1992, Tilvis et al. 1996, Masaki et al. 1998, Wu et al.
2009). Among community-dwelling, non-instutionalized persons living in the USA, its
prevalence increased from 15 % in the age group 65-69 up to 26 % in those aged 85+ (Rutan
et al. 1992). Masaki et al. (1998) had lower prevalences (5.1 % - 10.9 % between age groups
of 71-74 to 85+) in men living in Hawaii. Diabetes increases the prevalence of OH. In the
study of Wu et al. (2009), the prevalence of OH increased from 13.8 % (normal glucose
tolerance) to 17.7 % (pre-diabetes) and 25.5 % (diabetes). This study was conducted with
younger participants (mean age 39.4-57.7 years depending on the group). The OH is more
common in dementia with Lewy body, Alzheimer’s disease and Parkinson’s disease
compared to normal controls (Andersson et al. 2008, Sonnesyn et al. 2009). The prevalence
of OH/low blood pressure has claimed to be as high as 52 % in persons with dementia
(Passant et al. 1997), and it is common even in mild dementia (41 % and 14 % in dementia
and controls, respectively) (Sonnesyn et al. 2009).
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Figure 1. Etiology of orthostatic hypotension in older persons. Modified from Gupta and Lipsitz
(2007), Robertson (2008) and Low and Singer (2008).
   There are several factors which can increase the risk of OH e.g. age, smoking, low body
mass index, hypertension, reduced kidney function, intravascular volume depletion,
cardiac pump failure, venous pooling, carotid artery stenosis and carotid artery intima-
media thickness, dementia, Parkinson’s disease and other autonomic neuropathies (Rutan
et al. 1992, Senard et al. 1997, Rose et al. 2000, Poon and Braun 2005, Andersson et al. 2008,
Low 2008, Sonnesyn et al. 2009, Fedorowski et al. 2010b). In addition, reduced erythrocyte
mass or the normocytic, normochromic anemia of chronic autonomic failure will also
aggravate OH (Low and Singer 2008). In addition, COPD has been found to be associated
with OH (Robertson et al. 1998).
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   Furthermore, some drugs may evoke OH, such as antihypertensive compounds, -
adrenergic blocking agents, tizanidine (Shah et al. 2006), antidepressants (e.g. tricyclic
antidepressants, mianserin, paroxetine, sertraline, trazodone and venlafaxine, but not
bupropion or moclobemide) (Poon and Braun 2005, Darowski et al. 2009), antipsychotics
(e.g. clozapine, olanzapine, quetiapine and risperidone) (Mackin 2008), drugs for
Parkinson’s disease (Kujawa et al. 2000) and insulin (Madden et al. 2008). Conventional 1-
antagonists (e.g. prazosin, terazosin and doxazosin) which are used in the treatment of
benign prostatic hyperplasia have been associated with OH. However, in the study of
Ramdas et al. (2009), topical use of -blocker eye drops was not associated with an
increased risk in falling or dizziness when compared to the use of prostaglandin eye drops
(to which no cardiovascular side-effects are known) in older patients with ocular
hypertension or glaucoma. However, they stated that there may be an increased risk of OH
(Ramdas et al. 2009). OH is also more common when the number of regular medications
increase (Hiitola et al. 2009). In the study of Poon and Braun (2005) among veterans aged 75
years or more attending a geriatric clinic, the use of hydrochlorothiazide was associated
with the highest prevalence of OH, followed by lisinopril, trazodone, furosemide and
terazosin (65 % - 54 %). Patients with primary autonomic dysfunction or Parkinson’s
disease were excluded from the study.
2.6.3 Symptoms of OH
Symptoms of OH may vary from asymptomatic to severe. The typical symptoms of OH
include lightheadedness, dizziness, blurred vision, weakness, fatigue, transient cognitive
impairment, nausea, palpitations, tremors, headache and neckache (Consensus statement
1996).  However,  the  symptoms  may  also  be  atypical  such  as  lower  extremity  discomfort
and backache (Arbogast et al. 2009). In fact, asymptomatic OH has been claimed to be
rather common (Benvenuto and Krakoff 2011). Arbogast et al (2009) examined patients
(mean age 70.8 years) with a decrease in systolic blood pressure more than 60 mmHg
during a head-up tilt table test. They found that only 43 % of them had typical symptoms,
while 24 % had atypical symptoms and 33 % of subjects were asymptomatic. However most
patients with asymptomatic OH suffer subtle symptoms in situations where there is
increased orthostatic stress, such as after a meal, during elevated ambient temperature, or
after exertion (Low and Singer 2008).
2.6.4 Treatment of OH
Due to the several different causes of OH, its treatment may be challenging. Although OH
is  defined  through  strict  changes  in  blood  pressure,  its  treatment  should  not  be  aimed  to
achieve arbitary blood pressure goals. Instead, the treatment should be directed toward
ameliorating symptoms, correcting the underlying causes of OH when possible, improving
the patient’s functional status, and reducing the risk of complications (Gupta and Lipsitz
2007). Nonetheless, severe supine hypertension should be avoided (Low and Singer 2008).
Treatment of OH can be divided into nonpharmacological and, when necessary,
pharmacological interventions.
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2.6.4.1 Nonpharmacological therapies
When possible, the cause of OH should be treated. The first step involves careful
assessment  of  the  patient’s  medication  and,  if  possible,  removal  of  any  medication  that
could  precipitate  OH.  Possible  conditions  predisposing  to  OH  should  be  corrected  e.g.
initiation of fluid replacement therapy to dehydrated patients; in fact a reasonable daily
fluid intake is important for all older persons, in addition to salt supplementation (Low and
Singer 2008).
   Patient education is an important part of management of OH (Freeman 2008, Low and
Singer 2008, Medow et al. 2008). Orthostatic demands are fairly constant throughout the
day  and  if  the  subject  is  made  aware  of  his/her  orthostatic  blood  pressure  pattern,  many
patients can plan their activities accordingly (Medow et al. 2008). Activities that decrease
the venous return to the heart (coughing, straining, prolonged standing) should be avoided,
especially in hot weather. Blood pressure may also increase with dorsiflexion of the feet
before assuming upright posture, squatting and stooping forward. In addition, physical
counter-manouvers (toe raising, leg crossing, thigh contraction, bending at the waist) may
be helpful. Furthermore, waist high compression stockings and abdominal binders, as well
as raising the head of the bed by 10-20 degrees at night have been claimed to be helpful
(Gupta and Lipsitz 2007, Low and Singer 2008). Careful dietary instruction (e.g. avoiding
large meals, decreasing alcohol intake and adhering to low cholesterol diets) is also
important, since food evokes hypotensive responses secondary to postprandial shifts in
blood flow to the splanchnic bed (Medow et al. 2008).
2.6.4.2 Pharmacotherapy
If nonpharmacological interventions fail to improve the patient’s condition, a number of
pharmacological agents are available to treat OH. Fludrocortisone reduces salt loss and
expands blood volume (Gupta and Lipsitz 2007). It also increases the sensitivity of -
adrenoceptors (Low and Singer 2008). Midodrine (1-agonist) has selective vasopressor
properties and it is effective in OH treatment.
   However, both of these drugs cause supine hypertension (Low and Singer 2008).
Baroreflex unloading occurs mainly with standing and is negligible when the patient is
supine. Since neurotransmission in the autonomic ganglia is mediated by acetylcholine, it
has been hypothesized that pyridostigmine (cholinesterase inhibitor) could improve
ganglionic transmission primarily when the patient is standing, it should increase
orthostatic blood pressure without worsening of supine blood pressure. Although in a
study with older patients with severe autonomic failure pyridostigmine had no effect on
OH (Shibao et al. 2010), others have indicated that it may be adequate for patients with
mild OH (Low and Singer 2008).
   There are also other drugs with a pressor effect,  but their role in the treatment of OH is
controversial (Low and Singer 2008). The vasodilating effects of prostaglandins may be
blocked by prostaglandin inhibitors, and this has been beneficial in some OH patients. In
addition, non-steroidal anti-inflammatory drugs reduce sodium excretion, thereby causing
volume expansion (Medow et al. 2008). Caffeine inhibits adenosine-induced vasodilatation
by blocking adenosine receptors. Erythropoietin may be effective in patients with anemia
and autonomic dysfunction. Clonidine (2-adrenergic agonist) may be beneficial in patients
with  CNS  causes  of  autonomic  failure.  Yohimbine  (central  2-adrenergic antagonist) may
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also increase central sympathetic outflow in some patients with residual sympathetic
nervous system efferent output (Gupta and Lipsitz 2007) and has been effective with
patients with severe autonomic failure (Shibao et al. 2010). Nonselective -blockers,
particularly those with intrinsic sympathomimetic activity (e.g. pindolol) may have some
effect,  possibly  due  to  the  blockage  of  vasodilating  2-receptors allowing unopposed -
adrenoceptor mediated vasoconstrictor effects to predominate (Freeman 2008). In addition,
metoclopramide has been effective in OH treatment, probably due to vasoconstriction
(Gupta 2005).
   A new approach in the treatment of neurogenic OH has been the use of droxidopa. This is
a prodrug that is converted by dopa decarboxylase into noradrenaline outside the CNS,
therefore  ameliorating  the  symptoms  of  OH  in  patients  with  neurogenic  OH  due  to
degenerative autonomic disorders (Kaufmann 2008, Mathias 2008).
When  considering  older  persons,  pharmacological  treatment  of  OH  needs  to  be
considered with caution, especially for the drugs for which there are unconvincing results,
as several drugs listed above (non-steroidal anti-inflammatory drugs, clonidine,
metoclopramide) are not recommended for older persons due to their adverse effects (The
American Geriatrics Society 2012 Beers Criteria Update Expert Panel). One must also bear
in mind, that pharmacologic therapy alone is often inadequate, and non-pharmacological
measures,  including  patient  education,  must  represent  the  firm  foundation  for  an  overall
treatment plan (Medow et al. 2008).
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3 Aims of the Study
The purpose of this study was to examine some aspects (shown below) of pharmacotherapy
in older persons. The specific aims were:
1. To examine which symptoms are experienced as drug-related by patients, and whether
these are concordant with the judgment of the physician.
2.  To  find  out,  whether  the  results  of  the  SAA  assay  associate  with  published  ranked
anticholinergic lists and whether SAA or ranked anticholinergic lists are applicable in
determining the anticholinergic burden and anticholinergic adverse reactions during drug
therapy.
3.  To  investigate  the  effect  of  CGA  on  drug  use  in  general  and  on  the  prevalence  of
orthostatic hypotension in particular.
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4 Materials and methods
4.1 THE GeMS STUDY
The GeMS study (Geriatric Multidisciplinary Strategy for the Good Care of the Elderly) is a
multi-disciplinary population-based health intervention study that took place between the
years 2004-2007. In the study, a random sample of 1000 people was drawn from all of the
people >75 years living in the city of Kuopio (88 253 inhabitants, 5615 of whom were aged
>75 years), Eastern Finland on 1st November 2003. They were randomized with computer-
generated numbers into intervention (n=500) and control (n=500) groups. Of the
randomized subjects, 162 declined to attend to the study, 55 died before the examination
and 2 moved to a different municipality. The participation rate was 78 % (n=781) in the
entire population, 81 % (n=404) in the intervention group and 75 % (n=377) in the control
group. At baseline, 233 of the participants were men and 548 women with a mean age 81.7
years (range 75.3 – 99.0). The vast majority (n=700) were home-dwelling and 81 were living
in institutionalized care.
   Those 781 persons who participated in the study, underwent a structured clinical
examination and an interview conducted by three trained nurses in 2004. This was repeated
to all study subjects in 2005, 2006 and 2007. During the study, all participants had normal
access to primary and specialized health care.
   After  the  baseline  examination  by  the  trained  nurses,  the  subjects  in  the  intervention
group underwent a comprehensive geriatric assessment (CGA) annually between the years
2004-2006. During the CGA, they were examined by two physicians (trainees in geriatrics),
who performed an interview and clinical examination including a critical drug assessment.
If  needed,  the  physicians  made  new  diagnoses  or  referred  the  patient  to  a  specialist  (e.g.
ophthalmologist). In addition, two physiotherapists tested the patients’ functional capacity,
strength  and  balance  and  compiled  a  tailored  training  program  for  each  individual.  This
included an opportunity to participate in supervised muscle strength and balance training
once  a  week  in  a  gym,  with  the  emphasis  on  the  lower  limbs  to  increase  mobility
(Lihavainen  et  al.  2012).  Those  individuals  considered  to  be  at  risk  of  malnutrition  (short
form of MNA < 11, Nykänen et al. 2012) received also nutritional intervention from a
nutritionist. The tailored nutritional intervention consisted of two meetings with the
nutritionist in the years 2005 and 2006, and of telephone counselling at least every two
months during the intervention. In this intervention, the nutritionist helped the participants
draw up their own meal plan with enough energy and proteins, and aimed to reinforce the
dietary advice and to give additional support. In addition, two dentists examined the oral
health of the subjects at least twice during the study period (Komulainen et al. 2012). The
flow of the study subjects is shown in Figure 2.
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Figure 2. Flow chart of persons in the GeMS study during the years 2004-2007.
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The participants of the four studies were as follows:
Study I
In the first study, the study population consisted of those subjects in the intervention group
who attended into the study at 2004 (n=404). A total of 360 of those were home-dwelling at
the time of the investigation, and 44 individuals were in institutionalized care. Eight
patients did not respond to the question about adverse effects, mostly due to problems in
cognition or difficulties in speech.
Study II
The population of the Study II consisted of those whose blood samples were drawn in 2004
(total n=717, n=378 and n=339 for intervention and control groups, respectively) After
exclusion of the persons whose SAA samples were deemed unusable, the number of
participants was 621. Most of them were home-dwelling (n=563) and the number of persons
living in institutionalized care was 58. Subjects with and without dementia (n=129 and 492,
respectively) were analyzed separately, since dementia may itself have an effect on some of
the outcomes studied.
Study III
The population of the Study III consisted of the home-dwelling population in the
intervention and control groups, who attended to the GeMS study in years 2004 and 2005
(n=331 and n=313 for intervention and control groups, respectively). Flow chart of persons
in this study is presented in the article (III).
Study IV
In this study, the population consisted of persons (home-dwelling and in institutionalized
care)  in  whom the orthostatic  BP measurements  were  performed at  least  once  during the
GeMS study, and therefore the number of participants varied between the years. At
baseline, the number of participants was 697 (n=365 and n=332 for intervention and control
groups, respectively). The number of participants decreased every year of the study and at
the end of the study, the number of participants tested for OH was 583 (n=304 and n=279
for intervention and control groups, respectively). Flow chart of persons in this study is
presented in the article (IV).
4.2 DATA COLLECTION
The participants were annually interviewed by three trained nurses at the outpatient clinic.
The structured interview and examination included items pertaining to sociodemographic
factors,  living  conditions,  social  contacts,  health  behavior  and  state  of  health  and  also
measurements of blood pressure and orthostatic tests. The protocol also included
laboratory tests (serum electrolytes, complete blood count, glucose, thyroid hormone,
lipids, albumin and vitamin B12 levels) in the years 2004 and 2006. Blood samples for
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subsequent measurements of anticholinergic levels were also stored at -70oC prior to
analyses.  The subjects  were  asked to  bring along their  prescription forms and medication
containers  to  the  interview.  If  the  individual  could  not  answer  the  questions,  the
information was provided by a close relative or caregiver. Among other questions, they
were asked about possible drug-related adverse effects using an open type of questioning
(“Have you had problems with your medication, e.g. adverse effects or has a drug that you
were using been changed or discontinued due to an adverse effect?”) The researchers had
also access to medical records from the municipal health centre, home nursing service, local
hospitals and Kuopio University Hospital. If the subject was unable to visit the outpatient
clinic, a home visit was made by a trained nurse to conduct the interview and examination
and to check the use of drugs. Hospitalized subjects or those living in a nursing home were
interviewed and examined in their current residence.
   The physician interviewed and examined patients in the intervention group generally
within two weeks after the nurse’s interview and examination. The physician had access to
the information recorded by the nurse. The clinical examination included a careful
evaluation of cognition, mood, orthostatic reactions as well as the presence of possible
adverse drug events. The physician also evaluated the indications for all drugs in use, and
those  drugs  without  an  indication  were  withdrawn.  When  necessary  (e.g.  in  case  of  new
diagnoses as result of clinical examination), the patient’s medication was adjusted.
   Health experience (subjective health) was inquired during the interview by the study
nurse by a question “How you describe your present health?” with 5 options to answer
(1=good, 2= quite good, 3=mediocre, 4=quite poor, 5=poor).
4.2.1 SAA assay (II)
The assay was based on the method of Tune and Coyle (1980). It measures the level of
unbound  anticholinergic  activity  in  serum  by  displacement  of  a  radioligand  from
muscarinic receptors. Muscarinic receptor antagonists compete with L-quinuclidinyl
[phenyl-4-3H] benzylate (QNB) (Amersham Biosciences, Germany) and proportionally
reduce its binding to the receptors. The binding of tritiated QNB to membranes containing
muscarinic receptors from Wistar rat cerebral cortex and striatum was measured in the
presence of atropine as an anticholinergic standard, and in the presence of compounds with
anticholinergic activity in the serum samples.
   Membranes were prepared by sonicating and centrifuging fresh Wistar rat cerebral cortex
and striatum sample, after which the supernatant was frozen at -70°C. Serum samples were
also stored in -70oC.
   Protein concentration was assayed and adjusted to approximately 1.5 mg/ml with assay
buffer. The assay was performed in a 1 ml/well 96-well plate, to which atropine standard or
patient’s serum was pipetted to followed by tritiated QNB. Finally, rat brain membrane
preparation was added.
After incubation up to 1 h, the reaction was stopped by filtration on glass fibre filters.
Samples were washed with polyethylenimine and air-dried. Scintillation mats were then
melted on the filters and radioactivity measured in Wallac MicroBeta counter (PerkinElmer,
USA).
38
   Prior to the assay on human samples, the proper final concentrations and amounts of the
individual  components  in  the  incubation  solution  were  optimised.  To  avoid  animal  to
animal differences on the level of muscarinic receptors on rat cortex membrane
preparations, these were assayed in different samples. Saturation curves were assayed for
tritiated QNB, the optimal protein concentration was determined and a suitable calibration
curve was set. The concentration range of the labelled ligand was between 0.1 and 1 times
the dissociation constant. In all assays, the concentration of the binding sites in the rat
cortex membrane preparation added to the binding assay was between 0.2-1 mg of
protein/ml. Variability of the counts per minute readings was verified to be normally
distributed and despite the variance in the mean readings, the precision was comparable
from  between  experiments.  Atropine  calibration  curves  and  an  internal  control  of  known
activity were included in each experiment.
4.2.2 Vision (II)
Both short- and long-distance vision were measured using E tables.
4.2.3 Measurements of cognitive capacity, mood and functional ability (II)
The focus was set separately on persons with and without dementia (n=129 and 492,
respectively), since dementia may itself have an effect on some of the outcomes studied
(MMSE, ADL and IADL). The cognitive capacity and mood of the participants were
assessed with Mini Mental State Examination (0-30 points, higher points indicate better
cognition) (Crum et al. 1993) and Geriatric Depression Scale (GDS-15) (0-15 points, higher
scores are suggestive of depression) (Yesavage et al. 1982), respectively. Basic functional
capacity (e.g. toileting, dressing) was assessed using Barthel Activities of Daily Living
Index (scale 0-100 points, with higher points indicating better function) (van der Putten et
al. 1999). Other activities like shopping and using the phone were assessed using Lawton &
Brody’s Instrumental Activities of Daily Living scale (0-8 points, higher points indicate
better function) (Lawton and Brody 1969).
4.2.4 Anticholinergic lists (II)
In Study II, three different published anticholinergic lists were used. The Anticholinergic
drug scale (ADS) devised by Carnahan et al. (2006) includes 536 drugs, including 419
classified as having no anticholinergic activity. The ADS includes also drug doses in the
determination of anticholinergic activity. The Anticholinergic Risk Scale (ARS) was
published by Rudolph et al. (2008). It includes 49 drugs which all possess anticholinergic
activity and is based on the drugs most commonly prescribed within the Veterans Affairs
Boston Healthcare System. The third list used in the study (Chew et al. 2008) is based on the
in vitro affinity  on muscarinic  receptors  and includes  107  drugs  commonly used by older
persons with 85 of them classified as having no or minimal anticholinergic activity.
4.2.5 Causative medication (IV)
In Study IV, the list of causative drugs (ie. drugs associated with OH) was compiled based
on the literature (Baldessarini 2006, Baldessarini and Tarazi 2006, Gupta and Lipsitz 2007,
Robertson 2008) and clinical judgment (by Professors Sirpa Hartikainen and Risto
Huupponen) (Table 9).
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Table 9. Classification of drugs associated with OH (ATC code) used in the study.
Cardiac therapy (C01) Bromocryptine (G02CB01)
Antihypertensives (C02) Sildenafil (G04BE03)
Diuretics (C03) Tizanidine (M03BX02)
Peripheral vasodilators (C04) Opioids (N02A)
Vasoprotectives (C05) Dopaminergic drugs for Parkinson’s disease (N04B)
-blockers (C07) Antipsychotics (N05A)
Calcium channel blockers (C08) Tricyclic antidepressants (N06AA)
Drugs affecting renin-angiotensin-aldosterone
system (C09)
Non-selective monoamine oxidase inhibitors (N06AF)
4.2.6 Statistics (I – IV)
Data were entered into the SPSS statistical software (SPSS Inc., Chicago, USA). Different
versions of the software were used, versions 11.5 and 14.0 (I), and versions 17.0 and 19.0
(IV). In addition, SAS software, version 9.1 (III) and 9.2 (II) (SAS Institute, Inc., Cary, NC,
USA) and Prism software (version 5.03, GraphPad Software Inc., USA) (IV) were used.
      In Study II, the differences between anticholinergic drug use among the three lists
studied  were  analysed  with  two-way  ANOVA.  The  other  results  in Study II were  not
normally distributed, and therefore Kruskal-Wallis one-way analysis of variance test was
used. In Study III, unadjusted odds ratios and their 95 % confidence intervals were
calculated, and in Study IV,  differences  between  groups  with  different  OH  status  were
tested with Pearson chi-square test for categorical variables and with Mann-Whitney U test
for continuous variables.
   In addition, Markov models were used in Study IV in  the  measurement  of  CGA  on
orthostatic hypotension. The manifest Markov model was used to model change over time
in observed categorical variables by estimating conditional probablilities of moving from
one state at one period to another state at another period. Latent Markov model permitted a
more accurate estimation of stability and change by separating variability due to
measurement error from true change on the latent level. In Markov models, the individual's
current state was determined by his/her behaviour during the period immediately
preceding the test (first-order process).
4.2.7 Ethical issues
The participants or their relatives signed written informed consent to the study. This study
was approved by the Research Ethics Committee of the Hospital District of Northern Savo.
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5 Results
5.1 MAIN CHARACTERISTICS OF THE STUDY POPULATION AT BASELINE
Main characteristics  and the  most  common medical  conditions  of  the  study population at
baseline (in the year 2004) in the population attending to the GeMS study (n=781) are
shown in Tables 10-11. The data in Table 11 is based on the special reimbursement codes by
the Social Insurance Institution of Finland.
Table 10. Main characteristics of the study population at baseline.
Home-dwelling Institutionalized All
n 700 81 781
Age, mean (range) 81.3 (75.3-99.0) 85.6 (75.6-98.6) 81.7 (75.3-99.0)
Sex, n (%)
 -male 214 (30.6) 19 (23.5) 233 (29.8)
 -female 486 (69.4) 62 (76.5) 548 (70.2)
Education <6 years, n (%) 342 (48.9) 16 (19.8) 358 (45.8)
MMSE <25, n (%) 221 (31.6) 68 (84.0) 289 (37.0)
GDS >5, n (%) 34 (4.9) 12 (14.8) 46 (5.9)
Barthel <80, n (%) 36 (9) 61 (75.3) 97 (12.4)
IADL <6, n (%) 242 (34.6) 61 (75.3) 303 (38.8)
Table 11. The most common medical conditions in the study population (n=781) at baseline.
Medical condition n
Hypertension 305
Coronary heart disease 241
Cardiac failure 106
Dyslipidemia associated with coronary heart disease 74
Glaucoma 73
Asthma and COPD 68
Diabetes 56
Alzheimer's disease 51
Hypothyreosis 45
Rheumatoid arthritis, disseminated connective tissue disorders 42
Chronic cardiac arrhythmia 41
5.2 POTENTIAL ADVERSE DRUG REACTIONS ACCORDING TO PATIENTS
AND PHYSICIANS (I)
At the beginning of the GeMS study, there was a marked disparity between adverse drug
reactions reported by the patients (n=404) and those observed by the physician in the
intervention group. Out of 404 patients, almost all (n=399, 98.8 %) were using at least one
drug either regularly or on an on-demand-basis, with 390 (96.5 %) using drugs regularly at
time  of  the  clinical  examination.  The  most  widely  used  drug  classes  were  cardiovascular
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and  nervous  system  drugs,  drugs  affecting  blood  or  blood  forming  organs,  as  well  as
digestive tract and metabolism drugs. The mean number of regular drugs per patient was
5.2 (range 0-23, median 5) and on-demand drugs 1.4 (range 0-18, median 1).
   Most of the patients did not have any apparent adverse drug reactions (n=215, 53.2 % of
the sample). However, the physician did detect some drug-related adverse reaction at the
time of the investigation in 97 patients (24.0 %), while only 46 patients (11.4 %) reported
that they have or have had at least one drug-related adverse reaction.
   The mean number of drugs in use increased with adverse reactions; while the mean
number of drugs in those patients without either self-perceived or physician-detected
adverse reactions were 5.4 (4.9-5.9) (mean (95 % confidence interval (CI))) drugs, the
number increased to 7.3 (6.0-8.6) and 9.0 (8.2-9.7) with those who self-reported adverse
drug reactions and in whom physician identified adverse drug reactions, respectively.
   In general, the potential adverse reactions identified by the physicians and reported by
the patients differed substantially. The types of adverse reactions are shown in Table 12.
The physicians identified mainly adverse reactions related to the cardiovascular system,
central  nervous  system,  dry  mouth,  and  gastrointestinal  and  urinary  tract,  while  patients
reported mainly adverse reactions related to skin, central nervous system and
gastrointestinal tract.
Table 12. The  number  of  potential  adverse  drug  reactions  among  the  study  group.  OH  =
orthostatic hypotension, EP = extrapyramidal.
 Adverse reaction Identified by the physician (n=97) Reported by the patient (n=46)
Xerostomia 15 1
Cardiovascular 52 0
-OH 49 0
CNS 28 18
-EP symptoms 14 1
Gastrointestinal 7 14
Urinary 6 0
-retention 4 0
Skin 1 19
Others 5 6
When the patients with self-reported adverse reactions and physician-diagnosed adverse
drug reactions were compared, only seven patients (1.7 % from the sample) belonged to
both groups. Furthermore, only four of these subjects reported the same adverse reaction
which  had  been  identified  by  the  physician;  in  the  other  three  patients  the  self-perceived
and physician-diagnosed adverse reactions did not coincide. One patient reported shaking,
and the physician suspected a drug-drug interaction due to the concomitant use of
citalopram  and  tramadol,  which  could  well  account  for  the  symptom  reported  by  the
patient (increased serotonergic tone). This patient is not included in the table, since the
physician had not categorized the finding as an adverse reaction.
   In institutionalized care, the frequency of adverse reactions observed by the physician
and self-reported by patients were 59.1 % and 4.5 %, respectively. On the other hand,
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among the home-dwelling population, the corresponding numbers were 23.6 % and 15.6 %,
respectively.
5.3 ANTICHOLINERGIC ADVERSE REACTIONS, RANKED LISTS AND SAA
ASSAY (II)
With respect to the drugs in regular use by the study population, Carnahan’s list covered 88
%, Chew’s list 51 % and Rudolph’s list 5 %. The SAA values of the study population varied
between 2.3 – 82.7 pmol/ml (median 9.3 pmol/ml) of atropine equivalents. When the SAA
values  were  measured against  the  outcomes (vision,  MMSE,  GDS,  ADL and IADL),  there
was no association in either of the study groups (persons with or without dementia). In
addition, there was no association between the number of regular drugs in use and SAA.
When SAA was compared with scores from the anticholinergic lists, only Chew’s list scores
were associated with the SAA values (p<0.05).
   The number of regular drugs in use was associated with all three anticholinergic lists in
both individuals without and with dementia. In those without dementia, there was a
statistically significant association with scores of all three ranked lists and short-distance
vision, MMSE, GDS, ADL and IADL.
   In the subjects with dementia, these associations were weaker, an association was found
only  for  short-distance  vision  and  lists  by  Chew  and  Carnahan  as  well  as  for  ADL  and
IADL and lists by Carnahan and Rudolph.
5.4 EFFECT OF CGA ON DRUG USE (III)
The study physicians revealed significant adverse-effects from existing medication in 35
patients, a significant risk of a drug-drug interaction in seven patients, the evident need for
modification of drug doses in 58 patients and suboptimal treatment of the disease with a
potential effect on survival or functionality in 56 patients. In 24 patients, the indication why
the medication had been prescribed was unclear. Three patients could not use their existing
medication. In addition, study physicians found 15 previously undiagnosed subjects with
Alzheimer’s disease and two patients with Lewy body disease. An appropriate treatment
regimen was initiated in these patients.
   During the follow-up, the mean number of regular and on-demand drugs in use increased
in both the intervention (from 4.7 to 5.2 and from 1.4 to 1.7, respectively) and control (from
4.8 to 5.2 and from 1.1 to 1.3, respectively) groups. In the cases with significant differences
in medication changes between intervention and control groups, there was always a higher
amount of changes in the intervention group. The alterations of medications are
summarized in Tables 13-14.
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Table 13. The therapeutic classes of regular drugs in which more statistically significant
changes occurred in the intervention group compared with the control group. Grouping is based
on the ATC classification (given in parenthesis).
New
prescriptions
Cessations
of medication
Increase
of dosage
Decrease
of dosage
Calcium in combination
with other drugs (A12AX)
Vitamins (A11) -adrenoceptor antagonists
(C07)
Cardiovascular
system drugs (C)
Acetylsalicylic acid
(B01AC06)
Calcium (A12AA) Agents acting on the renin-
angiotensin system (C09)
Nervous system drugs
(N)
Antihemorrhagics (B02)
Vitamin B12 and folic acid
(B03B)
Drugs for treatment of
bone diseases (M05)
Table 14. The  therapeutic  classes  of  on-demand  drugs  in  which  more  statistically  significant
changes occurred in the intervention group compared with the control group. Grouping is based
on the ATC classification (given in parenthesis).
New prescriptions Cessations of medication
Cardiac therapy (C01) Cardiac therapy (C01)
Hypnotics and sedatives (N05C) Anxiolytics (N05B)
Ophthalmologicals (S01)
The study physicians changed medication (regular or on-demand) in 200 patients,
including 173 initiations and 55 cessations of regular medications in 114 and 41 patients,
respectively (Table 15). In general, they were responsible for 35 % of new prescriptions, 16
% of drug cessations, 6 % of dose increases and 70 % of dose decreases. About 58 % of the
drugs initiated by the study physicians were still in force after one year. Health experience
was more frequently increased in the intervention than in the control group.
Table 15. The contribution of study physician (%) to all performed drug changes over the one-
year period in the intervention group.
Therapeutic group
New
prescriptions
Cessations
of drugs
Increase of
dose
Decrease of
dose
Alimentary tract and metabolism 38.0 6.1 15.8 13.3
Blood and blood forming organs 64.0 15.4 0.0 100.0
Cardiovascular system 12.7 16.7 4.7 63.9
Genito urinary system and sex hormones 21.1 5.6 0.0 100.0
Systemic hormonal preparations,
excluding sex hormones and insulins 55.6  0.0 0.0 100.0
Anti-infectives for systemic use 0.0 0.0 0.0 0.0
Musculo-skeletal system 59.1 30.4 0.0 50.0
Nervous system 40.8 29.0 7.7 105.6
Respiratory system 41.7 15.4
Sensory organs 0.0 0.0
TOTAL 35.4 15.6 6.4 69.9
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5.5 EFFECT OF CGA ON ORTHOSTATIC HYPOTENSION (IV)
During the study, the amount of OH-positive subjects declined from 123 (35.0 %) to 77 (28.0
%) in the intervention group, while their number increased from 105 (32.8 %) to 100 (40.8 %)
in the control group. The differences between the groups were statistically significant two
(31.0 % vs. 39.8 %, p=0.028) and three (28.0 % vs. 40.8 %, p=0.002) years after baseline.
   During the study, transitions of patients between OH-positive and OH-negative groups
were frequent (Table 16). There were no statistically significant differences between
intervention and control groups except in the transitions two to three years after baseline,
when individuals in the control group were over two times more likely to remain OH
positive than subjects in the intervention group (risk ratio (RR) 2.20, 95 % CI 1.36-3.55) and
only 0.64 times as likely to stay OH-negative as those in the intervention group (RR 0.64, 95
% CI 0.45-0.90).
   In the intervention group, BP was recorded for 267 subjects at every measurement point
while for 98 persons at least at one measurement point was missing. In the control group,
the corresponding figures were 208 and 124, respectively. Markov models were used to
examine stabilities and changes in OH status over time in both groups. The manifest
Markov model chain was applied, and subsequently extended to the latent Markov model
(LMM), which takes the possibility of measurement error into account.
Table 16. The number of persons whose OH status remained the same for 1-3 years during the
study.
OH-positive persons OH-negative persons
Intervention
group
Control
group Total
Intervention
group
Control
group Total
2004-05 45 38 83 169 135 304
2005-06 37 38 75 168 118 286
2006-07 32 53 85 144 97 241
2004-06 20 20 40 123 85 208
2005-07 14 21 35 118 77 195
2004-07 10 15 25 90 51 141
   Based on the LMM, significant group differences were detected. In the intervention
group, the transition probabilities to develop OH were 3.9 % lower than for the control
group and the transition probabilities to recover from OH were 10.1 % higher than for the
control group in each of the two consecutive waves. Transition probabilities to remain in
the OH-positive group were 9.3 % higher and, to remain in the OH-negative group 5.8 %
lower in the control group than in the intervention group.
   According to univariate LMMs with one covariate at a time for the OH state at baseline,
the odds of individuals aged 85 years or more having OH at the baseline were 1.6 times
(odds ratio (OR) 1.59, CI 1.05-2.40) greater than the odds of those aged 75 to 79 years old. In
addition, subjects with Parkinson’s disease were 3.7 times (OR 3.71, CI 1.17-11.75) more
likely to have OH during the study period. The existence of diabetes, hypertension,
coronary artery disease, cardiac insufficiency or dementia or use of drugs associated with
OH were not associated with having OH.
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   At baseline, there were 254 persons in the intervention group and 208 persons in the
control group using one or more regular drugs associated with OH (Table 17). The only
statistically significant difference between the groups occurred during the first year of the
intervention, when there were more dosage decreases of drugs associated with OH in the
intervention group.
Table 17. The number of patients in the intervention and control groups with changes in regular
medicines associated with OH throughout the study period.
Drugs associated with OH Intervention group Control group OR (95 % CI)
2004-2005: persons 2004 254 208
 initiations 101 78 1.10 (0.75-1.60)
 cessations 91 66 1.20 (0.81-1.77)
 dose increases 42 27 1.33 (0.79-2.24)
 dose decreases 52 27 1.73 (1.04-2.86) *
2005-2006: persons 2005 247 193
 initiations 83 61 1.10 (0.73-1.64)
 cessations 62 46 1.07 (0.69-1.66)
 dose increases 38 21 1.49 (0.84-2.63)
 dose decreases 37 27 1.08 (0.63-1.85)
2006-2007: persons 2006 226 203
 initiations 79 64 1.17 (0.78-1.75)
 cessations 58 51 1.03 (0.67-1.59)
 dose increases 33 36 0.79 (0.47-1.33)
 dose decreases 33 25 1.22 (0.70-2.13)
Statistically significant changes are shown with *.
When medication changes were measured against OH status, statistically significant
changes  emerged  in  the  intervention  group,  as  drugs  associated  with  OH  (Table  9)  were
cancelled more often in OH-positive than in OH-negative subjects during the second year
of the intervention, and more dosage increases in the OH-associated medication occurred in
the OH-positive than in OH-negative subjects during the third year of the intervention
(Table 18).
Table 18. The number of patients in the intervention and control groups with changes in regular
medicines associated with OH throughout the study period.
Drugs associated
with OH
Intervention group Control group
OH+ OH- OR (95 % CI) OH+ OH- OR (95 % CI)
2004-2005: persons 2004 89 165 72 136
 initiations 33 68 0.84 (0.49-1.43) 14 64 0.27 (0.14-0.53) *
 cessations 38 53 1.57 (0.92-2.68) 16 50 0.49 (0.26-0.95)
 dose increases 14 28 0.91 (0.45-1.84) 9 18 0.94 (0.40-2.21)
 dose decreases 23 29 1.63 (0.88-3.04) 13 14 1.92 (0.85-4.34)
2005-2006: persons 2005 63 184 50 143
 initiations 24 59 1.30 (0.72-2.36) 14 47 0.79 (0.39-1.61)
 cessations 23 39 2.14 (1.15-3.99) * 10 36 0.74 (0.34-1.64)
 dose increases 12 26 1.43 (0.67-3.04) 5 16 0.88 (0.31-2.55)
 dose decreases 14 23 2.00 (0.96-4.18) 9 18 1.52 (0.64-3.65)
2006-2007: persons 2006 69 157 80 123
 initiations 21 58 0.75 (0.41-1.37) 21 43 0.66 (0.36-1.23)
 cessations 16 42 0.83 (0.43-1.60) 20 31 0.99 (0.52-1.89)
 dose increases 15 18 2.15 (1.01-4.56) * 12 24 0.73 (0.34-1.55)
 dose decreases 12 21 1.36 (0.63-2.96) 10 15 1.03 (0.44-2.42)
Statistically significant changes are shown with *.
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In the control group, less initiations of OH-associated regular and on-demand drugs took
place in the OH-positive than in OH-negative patients with respect to OH-associated
regular and on-demand drugs, respectively, during the first year after baseline (Tables 19-
20). There were no other statistically significant changes between the groups and/or OH
status in on-demand medication.
Table 19. The number of patients in the intervention and control groups with changes in on-
demand medicines associated with OH throughout the study period.
Drugs associated with OH Intervention group Control group OR (95 % CI)
2004-2005: persons 2004 105 63
 initiations 54 26 1.51 (0.80-2.83)
 cessations 29 19 0.88 (0.44-1.76)
2005-2006: persons 2005 120 63
 initiations 45 15 1.92 (0.97-3.82)
 cessations 28 14 1.07 (0.51-2.21)
2006-2007: persons 2006 112 61
 initiations 33 14 1.40 (0.68-2.89)
 cessations 26 14 1.02 (0.48-2.13)
Table 20. The  number  of  patients  in  the  intervention  and  control  groups  with  changes  in  on-
demand medicines associated with OH throughout the study period.
Drugs associated
with OH
Intervention group Control group
OH+ OH- OR (95 % CI) OH+ OH- OR (95 % CI)
2004-2005: persons 2004 36 69 22 41
 initiations 16 38 0.65 (0.29-1.47) 4 22 0.19 (0.06-0.67) *
 cessations 9 20 0.82 (0.33-2.04) 4 15 0.39 (0.11-1.35)
2005-2006: persons 2005 28 92 18 45
 initiations 11 34 1.10 (0.46-2.63) 6 9 2.00 (0.59-6.79)
 cessations 5 23 0.65 (0.22-1.91) 5 9 1.54 (0.43-5.44)
2006-2007: persons 2006 37 75 24 37
 initiations 11 22 1.02 (0.43-2.41) 6 8 1.21 (0.36-4.06)
 cessations 9 17 1.10 (0.43-2.77) 4 10 0.54 (0.15-1.97)
Statistically significant changes are shown with *.
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6 Discussion
6.1 METHODOLOGICAL CONSIDERATIONS
The GeMS study was a population-based intervention study with a random sample of 1000
persons aged at least 75 years living in Kuopio area at the beginning of the study in 2004. At
baseline, the response rate of the study was 78.1 %, which can be considered as adequate
(Jesson 2001). The population attending the study was rather heterogenous, from home-
dwelling persons with no regular drugs in use to institutionalized persons with several
morbidities, reflecting the health status of this age group (Cho et al. 2011). The results are
therefore likely to be generalizable to older persons living in Kuopio area. As the
population of Finland is ethnically homogenous and health care provided by municipalities
is organized according to a national framework (Ministry of Social Affairs and Health
2008), the results are also likely to be generalizable to older persons throughout Finland.
However, the generalizability of the results to countries with different health care systems
may be limited.
   CGA is a multi-disciplinary assessment. In addition to the physician, the team has
included members (generally 4-5) from different specialities such as nurses,
physiotherapists, social workers, nutritionists, occupational therapists, pharmacists,
audiologists, dentists, psychologists, and pastoral carers (Ellis and Langhorne 2005).
However, in some studies, the team has consisted of only a physician and a nurse (Stuck et
al. 1995, Li et al. 2010). The CGA team in the GeMS study consisted of physicians, trained
nurses, dentists, a physiotherapist and a nutritionist, thus representing the comprehensive
CGA team.
   Data collection of the study was performed by trained personnel, who conducted the
study following written guidelines. The accuracy of medical and medication data was
verified using patient records from the municipial health centre and Kuopio University
Hospital, resulting in well-documented data about medication use. A care manager (study
nurse or physiotherapist) was appointed for every patient participating in the study. The
CGA team (including physicians, study nurses, physiotherapist and nutritionist) had
weekly meetings with a geriatrician (Sirpa Hartikainen) to discuss about the patients and to
receive guidance, ensuring continual senior support.
   In addition, study physicians had separate meetings with Prof. Hartikainen to discuss
about patients’ medication, diagnoses, need for referrals and treatment plans. They also
received training about ADRs. When assessing the medication, they focused on the
appropriateness of medication, indications and dosages with special attention being paid to
the use of psychotropic agents.
   The  individuals  attending  the  GeMS  study  were  old,  and  therefore  some  loss  in
participants during the study period was to be expected. At the end of the study in 2007, 78
% of those who participated to the study at baseline were still attending in both groups. The
first three studies of this thesis concentrated on the baseline (I, II) or on the first year of the
GeMS study (2004-2005) (III).  The  last  study  (IV) was the only one in which patient loss
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would have played a role, since this examined the participants during the whole trial
period (2004-2007). This loss was taken into account by using Markov models.
   The instruments used in this study to measure potential anticholinergic ADEs (i.e. IADL
(Barberger-Gateau et al. 1992, Landi et al. 2000, Kauppi et al. 2005, Vittengl et al. 2006), ADL
(Stone et al. 1994, Landi et al. 2000, Odlund Olin et al. 2005, Venturelli et al. 2011), GDS-15
(Burke et al. 1991, Vinkers et al. 2004, Smalbrugge et al. 2008) and MMSE (Naugle and
Kawczac 1989, Landi et al. 2000, Boban et al. 2012)) have been widely used in geriatric
epidemiology and therefore should be applicable for our population.
   The anticholinergic lists compiled in this study have been used in several studies (e.g.
ADS (Nebes et al. 2012, Bhattacharya et al. 2011, Boudreau et al. 2011, Chatterjee et al. 2010,
Low et al. 2009), ARS (Nebes et al. 2012, Kumpula et al. 2011, Lowry et al. 2011a, Lowry et
al. 2011b, Koshoedo et al. 2012) and Chew (Ehrt et al. 2010)). However, it remains an open
question whether these lists truly measure anticholinergic ADRs. There are several other
items that may cause similar effects to those evoked by anticholinergic drugs (see Table 4).
   However, there are also some limitations to be taken into consideration. The CGA was
generally performed within two weeks after the nurse’s interview, and although in some
cases  changes  in  the  subject's  medication or  health  status  may have occurred,  those  were
rare. In addition, the participants in the GeMS study were examined only once a year, and
therefore data on medication and physiological status is available only on an annual basis.
It is likely that during that period, there could have been short-term changes in health
status and subsequently in the medication (e.g. infections treated with antibiotics, increase
of cardiac failure medication as a response to decreased physiological status due to
infections etc.), but no information about these events is available.
   Due to the multi-disciplinary nature of the intervention, it is impossible to separate the
results of one aspect (e.g. the medication assessment) from the entire CGA. It is likely that
the beneficial effects seen on the study population (e.g. Lihavainen et al. 2012) result from
the sum of all changes achieved during the intervention process.
   Markov  models  were  developed  by  statistician  Piia  Lavikainen.  The  other  statistical
methods used here have been widely used in this type of study.
6.2. DISCUSSION OF THE RESULTS
6.2.1 Adverse reactions as assessed by patient and physician (I)
The result of the study was that physicians discovered more potential adverse reactions (24
%) than patients reported (11 %), but there was a great disparity between what adverse
reactions they reported.
   In the literature, ADRs have been reported to occur in a wide range between 6.7 % - 43 %,
depending on the setting (Lazarou et al. 1998, Camargo et al. 2006). However, these values
may not be accurate since generally only a small amount of ADRs are actually detected
(Hannan 1999). Furthermore, patients have tended to report higher amounts of ADRs than
physicians (Zimmerman et al. 2010, Gäwert et al. 2011), although also opposite results have
been published (Lorimer et al. 2012). The method of data collection may greatly affect the
reports of the patients. The application of a ‘rating-scale method’, in which the patient is
provided with a questionnaire listing potential side effects has increased reporting of side-
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effects experienced (Sheftell et al. 2004). In the GeMS study, the adverse drug effects were
inquired from the patients using an open type question "Have you had problems with your
medication, e.g. adverse effects or has a drug that you were using been changed or
discontinued  due  to  an  adverse  effect?"  It  is  possible  that  the  rating-scale  method  would
have produced more ADR reports from the patients. However, the open-type question is
closer to the reality in today’s clinical practice. Furthermore, the GeMS study was a
multidisciplinary study, in which the medication assessment was only one component, and
GeMS already involved quite large questionnaire panel to be answered by the patient.
Therefore, asking the patients to answer a wide rating-scale questionnaire may not have
been advisable since it would have greatly increased the number of questions to be
answered by the patient.
   Although  the  study  physicians  were  trainees  in  geriatrics,  they  had  had  long  clinical
experience  in  primary  care,  where  they  had  focused  on  geriatric  patients.  Thus,  the
physicians were experienced in treating elderly subjects and well motivated to focus on
possible drug-related problems. Unfortunately the situation is not so optimal in everyday
practice. It has been previously reported that physicians may under-report ADRs in clinical
settings (Moride et al. 1997). It has been claimed that electronic medical records may
improve detection of ADRs (Hannan 1999), and the possible utilization of National Archive
of Electronic Health Records (KanTa) in the future will hopefully result in a reduction in the
numbers of ADRs.
   The most frequently reported ADRs by patients were related to skin, CNS and
gastrointestinal tract; i.e. to readily observable ADRs. This is in agreement with a previous
study with patients with rheumatoid arthritis, who most often reported gastrointestinal and
skin disorders followed by general system disorders (Gäwert et al. 2011). In that study, the
highest  number  of  ADRs  detected  by  physicians  involved  gastrointestinal  disorders,
infections and skin disorders. However, relatively good agreement in the frequencies of
reports were found for vascular hypertensive disorders, oral soft tissue disorders and
cardiac arrhythmias. Patients were more likely to describe general system disorders, weight
changes, dizziness, headaches and vision disorders. However, despite similar overall
frequencies, the highest agreement between the physician and an individual patient was
still only at the level of one third for skin disorders and oral soft tissue conditions (Gäwert
et al. 2011).
   Therefore,  it  seems  that  physicians  focus  on  those  ADRs  that  may  have  more  serious
clinical consequences, but patients focus on those ADRs that they consider as harmful in
everyday life. Therefore, although physicians should actively seek for possible ADRs, they
should also take ADRs reported by patients into account. This would improve the quality
of life of the patient.
   OH  was  the  most  commonly  discovered  cardiovascular  ADR  by  the  physician.  As
previously reviewed in 2.6, OH is a common condition among older persons and may have
a great impact on their quality of life. In addition, there were also several cases of
extrapyramidal symptoms as well as urinary retention. These are ADRs that may be related
to the use of anticholinergic drugs.
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6.2.2 Association between ranked anticholinergic lists, SAA and anticholinergic adverse
reactions (II)
There were two main results in this study. First, there was no association between potential
adverse reactions and SAA levels. Second, the scores of the three anticholinergic ranked
lists (Chew, Carnahan and Rudolph) were associated with the outcomes.
   As described in the literature review (2.5.5), there is extensive heterogeneity in results
between SAA levels and clinical outcomes, e.g. in some reports MMSE has (Tune et al. 1981,
Golinger et al. 1987, Rovner et al. 1988, Flacker et al. 1997, Mulsant et al. 2003) or has not
(Chengappa et al. 2000) been associated with the SAA results. In addition, Mangoni et al.
(2012) found an association between SAA and Katz ADL index in older hip fracture
patients, however no association was found between SAA and Barthel’s ADL or Lawton-
Brody’s IADL in our study.
   In the present study, a weak, but statistically significant association was detected between
SAA values and Chew’s list but not with the ADS or ARS. In agreement with these results,
in the recent study of Mangoni et al. (2012), no association was found between SAA and
any  of  the  lists  they  utilized  (Rudolph’s  ARS,  Carnahan’s  ADS,  Anticholinergic  Burden
Scale or anticholinergic component of Drug Burden Index). The ARS score, unlike the other
lists, was associated with 3-month mortality. There do not appear to be any other studies
investigating the association between the ranked lists and SAA.
   However, the present study detected a significant association between the ranked lists
and several potential anticholinergic ADRs in individuals without dementia. Short-distance
vision, but not long-distance vision, was associated with higher scores in the three studied
lists. In addition, cognition, mood and function were affected by the increasing scores. This
indicates that the ranked lists of anticholinergic drugs may be useful in the determination
of potential ADRs. When the three lists are compared, the results of Carnahan’s and Chew’s
lists match quite well with each other with a logical decrease (or increase in case of GDS),
however the results with Rudolph’s list often produce divergent results with the highest
scores. This may be due to small number of individuals with the highest scores as identified
by Rudolph’s list. In summary, it is likely that the ARS is less useful in our population.
   Unlike the situation in individuals with normal cognition, no statistical significance was
achieved in MMSE or GDS among subjects with dementia. Most likely this results from the
small number of persons in this group. However, statistical significance was achieved in
changes  in  short-distance  vision and physical  function as  measured with ADL and IADL,
indicating that patients suffering from dementia are more vulnerable to the anticholinergic
ADRs than their counterparts with normal cognition. The levels of acetylcholine decrease
with increasing age and especially in patients with dementia (Johnell and Fastbom 2008),
resulting in greater susceptibility to anticholinergic drugs. Therefore, even drugs with mild
anticholinergic effects may have dramatical effect to persons with dementia.
   The ARS has been reported to be associated with both central and peripheral
anticholinergic ADRs (Rudolph et al. 2008). Therefore, it is somewhat surprising that its
associations with measured ADRs were poorer than with the Chew’s list (based on in vitro
measurements) or on the ADS (based on the medications’ contribution to the SAA).
   Although the ADS scores have been associated with SAA scores (Carnahan et al. 2006),
this could not be confirmed in the present work. The SAA assay is based on biological
samples and is possible that different sources of brain homogenate may have an effect on
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the assay. In addition, there are issues related to the patient (e.g. endogenous
anticholinergic activity, unrecognized cholinergic drugs in use binding to the muscarinic
receptors) that may affect the results. This is seen also in the variety of the baseline results
encountered in the patients irrespective of their anticholinergic drug use (Flacker and Wei
2001, Mulsant et al. 2003). Furthermore, although there has been an association between
SAA  and  delirium  and  delirium  resolution  has  been  accompanied  by  a  decrease  in  SAA,
that change was often not attributable to any discontinuation or reduction in
anticholinergic medication (Carnahan et al. 2002a). In addition, the different ability of
different drugs to pass the blood-brain barrier (Kay et al. 2005), which is not taken into
account  when  measuring  the  SAA,  may  have  an  important  impact  on  their  central
anticholinergic effects.
   Our results confirm the proposal that anticholinergic drugs affect negatively on cognition
and short-distance vision. Unlike the SAA measurement, the ranked lists seem to be useful
in clinical practice in the measurement of the risk of anticholinergic ADRs.
6.2.3 Effect of CGA on drug use and orthostatic hypotension (III – IV)
The assessment of the effects of CGA focused on two questions: how a single CGA can
affect  the  drug  use  during  a  1-year  period,  and  can  the  prevalence  of  OH  be  reduced  by
using repeated annual interventions over a 3-year period.
   A single CGA did not decrease the number of medicines in use, but it did reduce the
number of inappropriate medication as defined by the Beer's criteria during the one-year
period.  When  performing  the  medication  assessment,  the  study  physicians  focused  on
indications of drugs in use, proper dosages and potential inappropriate medication. Basic
laboratory tests were conducted in the participants in years 2004 and 2006. In addition, the
study  physicians  focused  on  those  conditions  commonly  found  in  older  persons,  e.g.
dementia (Grossman et al. 2006), osteoporosis (Bonnick 2006), orthostatic hypotension (Low
2008) as well as low levels of vitamin B12 (Park  and  Johnson  2006)  and  folic  acid  (Lökk
2003). In addition, several initiations of vitamin B12 and folic acid as well as calcium-vitamin
D combinations (with subsequent cessations of plain vitamin D preparations) were made
by the study physicians. Furthermore, a substantial number of persons with OH were
identified.
   During the CGA, the indication for all drugs in use was carefully considered, with those
drugs without an indication being withdrawn. The study physicians focused especially on
CNS  drugs  which  are  commonly  used  by  older  persons  even  though  there  were  no
appropriate indications (Linjakumpu et al. 2002). However, these drugs had often been
used for a long time, and therefore their use needed to be tapered off carefully rather than a
prompt cessation and this was seen in the results. Other dosage modifications focused on
the drugs affecting the cardiovascular system, common conditions in the older persons. For
example, the treatment of hypertension is based on the concomitant use of several different
types of drugs, therefore requiring a careful consideration on their doses. When evaluating
the drugs associated with OH, there were no significant changes.
   In general, the increase of medicines in use is linked with drug-related problems (Viktil et
al. 2006), and therefore the decision to initiate a medication needs to be carefully
considered. In this study, the number of medicines in use increased over the one-year
period despite the CGA. On the other hand, old people often have several comorbidities
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which do require medication. Nonetheless, the amount of inappropriate drugs (as defined
by Beer's criteria) decreased, and the increases in the self-perceived health experience were
more frequent in the intervention group than in the control group. In general, an increase in
the number of prescribed drugs after CGA can be acknowledged as an acceptable outcome
when it aims to reduce situations of under-treatment (Sergi et al. 2011).
   Although the self-perceived health experience increased more frequently in the
intervention  group  than  in  the  control  group  one  year  after  the  first  CGA,  there  were  no
changes in the OH status between the groups at that timepoint. The beneficial effect in the
OH status in the intervention group was statistically significant only after repeated CGAs,
which is in line with previous studies (Stuck et al. 2002). There are several causes for OH,
some of which are irreversible (such as autonomic failure) (Figure 1). However, with proper
treatment e.g. in the case of diabetes, the development of OH may be at least slowed down.
   In addition, there are several other factors causing OH that can be modified, one of those
being the use of medicines. There are several drugs that may evoke OH, and therefore a
medication review is recommended in individuals with OH. In the present study, there
were no clear changes among these drugs in either the intervention or the control groups.
Thus,  the  decrease  in  prevalence  of  OH in  the  intervention group could not  be  explained
solely by medication changes.
   In  addition  to  clinical  examination  and  medication  review,  GeMS  patients  in  the
intervention group also underwent other interventions with a dentist, nutritionist and
physiotherapist. These may have achieved improvements in other factors that can affect on
OH  e.g.  nutrition,  fluid  balance  and  general  lifestyle.  The  mobility  of  patients  in  the
intervention group has been reported to improve (Lihavainen et al. 2011). It is therefore
likely that it was the overall improvement in the patients’ health status contributed also to
the improved OH status.
   In CGA, the results after changes in medication or other treatment need to be closely
monitored  and  further  adjustments  should  be  performed  based  on  the  results  of
monitoring. However, due to the lack of resources, this was not possible in the GeMS study
and therefore one can only speculate whether the results would have been better with more
frequent monitoring of the patients. The GeMS study was able to organize patient
examinations mainly only once a year. Most of the year, patients were treated by general
practitioners in health centres and specialists in special health care. Therefore, the study
physicians were not the primary treating physicians of the study population. The best
result  of  a  CGA is  likely  to  be  achieved when a  treating physician,  who ideally  has  been
known to the patient for a long time, performs the CGA. In addition to the benefit of
knowing the patient, this also would increase the adherence of the treating physician to the
treatment of the patient better than just receiving a report of a CGA performed by others.
This may also account for the number of ‘unchanges’ that were noticed during the one-year
period after the first CGA. Medication review should be performed at least once a year to
older persons with medications in use (Ministry of Social Affairs and Health 2007). This
frequency may be suitable for older persons with relatively stable medication and medical
conditions,  however  a  higher  frequency  would  often  be  beneficial  e.g.  when  a  new  drug
treatment is initiated.
   There are some limitations to the study. Although the BP measurements were performed
in a standardized manner, there were variations in the time of the measurements ranging
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from early  morning to  afternoon.  This  may have affected the  results,  since  the  OH status
varies over time, being most prevalent after rising up in the morning (Ooi et al. 1997). These
measurements were also performed only once, increasing the possibility of a measurement
error. In addition, delayed orthostatic hypotension was not assessed. As delayed OH may
be a mild or early form of sympathetic adrenergic failure (Podoleanu et al. 2009), its
assessment would have been interesting. Furthermore, the number of persons that could
not be evaluated was rather high. Moreover, the subjects included into the study varied
annually, although this could be taken into account by using the Markov model.
   Some  of  the  GeMS  participants  were  not  tested  for  OH.  The  main  reason  was  their
inability to adopt an upright posture required time for BP measurements. In general, those
subjects were in poorer condition than those who participated in this trial. It is known that
the prevalence of OH is even higher among demented and frail elderly individuals (Ooi et
al. 1997, Passant et al. 1997), and most likely this would have been the case also in the
present study. Therefore, special attention should be paid also to those individuals who
cannot co-operate in the orthostatic tests.
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7 Conclusions
1. Identification of adverse drug reactions
There is a disparity between patients and physician about adverse drug effects. The
recognition  by  patients  of  clinically  important  ADRs  such  as  OH  and  EP  symptoms  was
poor. On the other hand, patients report more ADEs that are easily observable than
physicians.
2. Use of SAA and anticholinergic ranked lists in determination of anticholinergic-like
ADRs
SAA is not an applicable tool for measuring anticholinergic adverse effects. The ranked
anticholinergic lists are more useful although their applicability in clinical practice would
be enhanced if they could be embedded into electronic databases and prescribing
programs. However, it is an open question whether these lists truly measure anticholinergic
effects.
3. Effect of CGA on medication and OH
CGA can be used to rationalize medication, however this effect may be partially
counteracted by other healthcare professionals. This harmful possibility would be
decreased if electronic patient records were available to all healthcare professionals, i.e. to
the personnel of municipal health centres, special health care and private practitioners.
CGA can also be used to decrease the prevalence of OH among old persons, but to be
sucessful this requires a time interval of years with repeated interventions.
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8 Implications for the Future
PRACTICAL IMPLICATIONS
1. Assessments of medication
A medication assessment should be performed for older persons at least annually,
however in cases of comorbidity or polypharmacy, it should be performed more often,
e.g. after the initiation of every new treatment.
2. Identification of adverse drug reactions
Physician should actively search for possible adverse drug reactions even though the
patient has not recognized and reported any drug related symptoms.
3. Identification of potential anticholinergic load on medication
Several drugs possess anticholinergic properties, and if these drugs act in an additive or
synergistic manner they may cause a decrease in cognition as well as other
anticholinergic adverse drug reactions. However, the anticholinergic properties of many
widely used drugs are not known. For the recognized anticholinergics, a database
embedded into normal practice would be useful.
IMPLICATIONS FOR RESEARCH
1. Drugs and older persons
The effects and adverse effects of drugs commonly used in older persons should be
evaluated in trials with older age study groups and patients with comorbid conditions.
2. Anticholinergic effects of drugs especially in aged persons
All of the anticholinergic effects of drugs are not known. In addition, several changes
occur with aging (e.g. increases in blood-brain barrier permeability) that may make
older persons more vulnerable to anticholinergic ADRs, however the scientific data
about these changes is greatly limited. Furthermore, a fast and reliable method is needed
with which to assess an individual's anticholinergic load.
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Aging is a heterogenous and indi-
vidual process. Therefore, an indi-
vidualized assessment of an older 
person’s health status including 
assessment of his/her medication is 
essential. This thesis investigated the 
effect of comprehensive geriatric as-
sessment, and especially the impact 
of a medication assessment in indi-
viduals aged ≥75 years focusing espe-
cially on the disparity on recognizion 
of adverse drug reactions by patients 
and their physician, the anticholiner-
gic adverse reactions, and the effect 
of CGA on drug use and orthostatic 
hypotension.
